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ABSTRACT OF DISSERTATION 
 
 
PATHOGENESIS OF INFLUENZA A VIRUS: INHIBITION OF MONOCYTE DIFFERENTIATION 
INTO DENDRITIC CELL 
 
Dendritic cells (DC) are a heterogeneous population of hematopoietic cells that play a 
versatile role in orchestrating immune responses against an array of invading 
pathogens, including influenza virus. These cells reside in lymphoid organs as well as in 
non-lymphoid tissues such as mucosal surfaces of respiratory and gastro-intestinal 
system. Recent investigations have suggested that in the steady state, dendritic cells are 
derived mainly from bone marrow precursor cells without a monocytic intermediate 
whereas during inflammation or infection, monocytes readily differentiate to generate 
monocyte derived dendritic cells (MoDC). The ability of virus infected monocytes to 
differentiate into MoDC was investigated and the results demonstrated that in vitro 
infection of monocytes with influenza virus impaired their development into MoDC. It 
was also observed that influenza infection of monocytes, pre-treated with GM-CSF and 
IL-4 for DC differentiation, was minimally-productive and non-cytopathic. In spite of 
successful viral genome transcription, viral protein synthesis was restricted at an early 
stage. However, despite of the limited replication, influenza virus infected monocytes 
failed to develop the distinctive DC- like morphology when cultured with GM-CSF and IL-
4 as compared to their mock infected counterparts. Infected cells, after 4 days in 
culture, expressed reduced amounts of CD11c, CD172a (myeloid marker), CD1w2 (CD1b) 
and CCR5. Influenza virus infected monocytes also retained substantial non-specific 
esterase activity, a characteristic for monocytes and macrophages. Antigen presentation 
capability of infected cells was also affected as indicated by decreased endocytosis. 
Production of IL-12, a pro-inflammatory cytokine and IL-10, a reciprocal inhibitory 
cytokine, was coordinately modified in influenza virus infected monocytes in order to 
arrest their differentiation into DCs. At least limited viral replication was necessary to 
impede the differentiation process completely. However, viral NS1 protein activity, as 
evidenced with a mutant influenza virus, was not essential for this inhibition. This 
identified a new strategy by influenza virus to interfere with DC differentiation and 
evade a virus specific immune response.   
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
  
  
Influenza is a term that was appropriated from Italian in the mid-1700s to 
describe a disease that was believed to be the “influence” of miasma (bad air) and stars. 
The causative agent of such “bad influences” and the pandemic that swept the world in 
1918 could only be identified in 1931, when Dr. Shope was able to reproduce an 
influenza like disease in healthy pigs by inoculating them with nasal wash from infected 
ones (1). Since then influenza virus has been the focus of intense research which has 
helped garner a very detailed knowledge about the molecular biology, pathogenesis and 
immune responses of the virus. 
 
1. Influenza virus 
 Influenza virus is a member of the viral family Orthomyxoviridae that includes 
negative sense, single strand RNA viruses. The etymology of orthomyxoviridae can be 
traced back to two Greek words: orthos (standard or correct) and myxa (mucus) which 
thereby adeptly characterizes the ability of these viruses to bind and infect through the 
host mucus membrane (2). This family of RNA viruses consists of five genera, namely 
Influenzavirus A, Influenzavirus B, Influenzavirus C, Thogatovirus and Isavirus (3). The 
first three genera each have one species or type: Influenza A virus, Influenza B virus and 
Influenza C virus respectively. Theses three types of influenza viruses – A, B and C are 
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distinguished based on the antigenic differences in their internal proteins, nucleocapsid 
(NP) and matrix (M) protein. Influenza A virus has a broad host range that spans both 
mammalian and avian species whereas influenza B virus can infect humans and seals, 
and influenza C virus is contained within humans and swine. The genus Thogotovirus has 
two species – Thogoto virus and Dhori virus. They mainly infect ticks but serological 
evidence suggests that humans and other mammals are also susceptible. These tick 
borne viruses are known to cause a febrile illness and encephalitis in humans. Infectious 
salmon anemia virus is the only known virus within the genus Isavirus which has been 
isolated from Atlantic salmons (3).  
 
  1.1. Influenza A virus 
 Influenza A virus is the primary causative pathogen for the seasonal, highly 
contagious, acute respiratory illness in humans and other mammals. Influenza A viruses 
are sub-divided into various sub-types on account of their antigenic identity of two 
major surface glycoproteins – hemagglutinin (HA) and neuraminidase (NA). Sixteen 
different HA and 9 NA variants have been identified so far (4). Wild aquatic birds 
(waterfowl, ducks, geese, swan, gulls, terns etc.) are considered the natural reservoir for 
all subtypes of influenza A virus. In wild aquatic birds, these viruses are benignly 
adapted and cause only asymptomatic infection. Viruses in these reservoir hosts are 
suggested to be in an evolutionary stasis, which is imperative for perpetual maintenance 
of a consistent viral gene pool. However, over the years, different subtypes of influenza 
A virus have successfully jumped from their natural reservoir hosts to other avian and 
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mammalian species to establish clinical diseases (5). All currently known subtypes of 
influenza A virus and their natural hosts are listed in table 1.1. 
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Table 1.1: Natural hosts of influenza A viruses. The table indicates the subtypes of 
hemagglutinin (HA) and neuraminidase (NA), and the hosts they have been identified 
in. 
Subtype                              Predominant host Subtype                                Predominant host 
H1                                       Human, pig, birds N1                                           Human, pig, birds 
H2                                       Human, pig, birds N2                                           Human, pig, birds 
H3                  Birds, human, pig, horse, dog* N3                                                                 Birds 
H4         Birds N4                                                                 Birds 
H5                                               Birds, (human) N5                                                                 Birds 
H6         Birds N6 Birds 
H7                                   Birds, horse, (human) N7                          Horse, birds 
H8                Birds N8                                        Horse, birds, dog* 
H9                                               Birds, (human) N9                Birds 
H10  Birds  
H11 Birds  
H12 Birds  
H13 Birds  
H14 Birds  
H15 Birds  
H16 Birds  
Adapted from Lamb RA, Krug RM. Orthomyxoviridae:the viruses and their replication. In: Knipe DM, 
Howley PM, Griffin DE et.al, editors, Fields Virology. 4th edition, 2001 
* Science 2005; 310: 482–485 
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1.2. Equine influenza virus 
 Equine influenza virus is one of the predominant causes of respiratory diseases 
in horses worldwide (6). The first isolate of equine influenza virus was isolated from an 
outbreak in Eastern Europe in 1956 and was indentified as an H7N7 subtype (influenza 
A/equine/Prague/56). Subsequently, in 1963, another subtype (H3N8, influenza 
A/equine/Miami/63) was isolated from horses in Miami, USA (7). Both subtypes 
cocirculated among horses for about fifteen years, during which (around 1970s) equine 
influenza viruses of the H7N7 subtype underwent reassortment with their H3N8 
counterparts and acquired all the internal genes (i.e. PB2, PB1, PA, NP and NS) except 
matrix gene (8). However, the H7N7 virus is believed to have ceased circulating after 
1977 since when no new isolates of this subtype has been identified from horses (9). 
The H3N8 virus continues to circulate and is responsible for all recent equine influenza 
outbreaks. Based on their antigenic and genetic variability, H3N8 equine influenza 
viruses are considered to have evolved into two divergent lineages: “American” and 
“Eurasian” (10). Although initially they were grouped based on their geographical 
distribution, some viruses from the American lineage were later isolated from the 
United Kingdom. Equine influenza viruses from the American lineage have again been 
sub-divided into three sub-lineages: South American, Kentucky and Florida (11). In 2004, 
H3N8 equine influenza viruses from the American lineage, in an unprecedented manner, 
were found to cross species-barrier to infect dogs (12). Since then some other H3N8 
equine influenza viruses from the European lineage have also been isolated from pigs 
which have raised a serious concern of probable host-expansion of these viruses (13).  
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2. Structure of influenza A virus     
2.1. Morphology  
 Influenza A viruses are small, pleomorphic particles. Spherical virions range from 
80 to 120 nm in diameter while filamentous particles can measure up to several 
micrometers in length. Fresh isolates are generally filamentous which changes into 
almost entirely spherical morphology following several passages (14). The virion, under 
electron microscope, shows two distinct layers – an evenly spaced outer zone (100 Å) 
covering a densely packed inner material (60-100 Å) (15). The outer zone or envelope 
consists of a host-derived lipid bi-layer within which the two surface glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA) remain embedded. M2 ion channels also 
protrude through this envelope. Within the lipid envelope M1 matrix proteins form the 
inner shell which encompasses the viral RNA genome. Each viral RNA segment remains 
encapsidated by multiple nucleoproteins (NP) in a helical symmetry to form the 
ribonucleoprotein (RNP) complex. Three RNA dependent RNA polymerase proteins (PB2, 
PB1 and PA) stay attached to the end of each viral RNA segment of the RNP complex 
(16).  
 
2.2. Viral genome and encoded proteins 
 The genome of Influenza A virus (about 13.6 kb) consists of 8 single strand 
negative sense RNA segments which altogether encode for eleven viral proteins. 
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2.2.1. PB2 
 The PB2 gene of influenza A virus is 2341 nucleotide long and encodes for a 85.7 
kDa polypeptide that constitutes one of the basic components of the heterotrimeric 
viral polymerase complex (16). The PB2 subunit plays a crucial role in viral mRNA 
transcription. It binds to the 5’-cap I structure (m7GpppNm) of host cell pre-mRNA 
which is later cleaved, in a process called “cap snatching”, to prime viral mRNA synthesis 
(17). The role of PB2 polymerase in viral RNA replication, although essential, is yet 
obscure.    
 
2.2.2. PB1 
 The PB1 gene of influenza A virus is the same in length as PB2 and it encodes the 
second basic subunit (MW 96.5 kDa) of the viral polymerase complex. It serves as a 
backbone that can bind to the other two polymerases as well as nucleoprotein (18, 19). 
PB1 is the catalytically active RNA dependent RNA polymerase which is involved in 
transcription initiation and elongation of messenger RNA (mRNA), complementary and 
viral RNA (cRNA and vRNA, respectively) in a sequence specific manner (17, 20). Other 
than the polymerase activity, PB1 also performs endonucleolytic cleavage of cellular 
mRNA to generate capped RNA primers for initiation of viral mRNA synthesis (21). 
Recently, a novel protein christened PB1-F2 has been identified to be expressed from an 
alternate open reading frame (+1 ORF) of PB1 gene. This viral protein (about 87 amino 
acids) localizes to the mitochondria and is emerging as an important player in influenza 
virus pathogenesis through induction of apoptosis (22).   
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2.2.3. PA 
 The third and the only acidic subunit (MW 84.2 kDa) of the viral polymerase 
complex is encoded by the PA gene which has a length of about 2233 nucleotides (16). 
Although particular functions of this polymerase protein have not been fully 
characterized, PA is known to interact with PB1, possess weak protease activity and play 
some yet unidentified role in both viral transcription and replication (18, 23, 24).  
 
2.2.4. HA 
 The fourth largest gene (1778 nucleotides) in influenza genome encodes for a 
membrane glycoprotein (MW 61.5 kDa monomer), hemagglutinin or HA (16). This major 
surface antigen of influenza virus is responsible for receptor binding and membrane 
fusion during viral entry into the cell. Each HA polypeptide has three sub-domains: 
receptor binding, vestigial esterase and fusion domain (25). Biological activation of HA 
requires three posttranslational modifications: (a) cleavage of the amino terminal signal 
peptide (14-18 a.a.); (b) glycosylation and palmitoylation; and (c) proteolytic cleavage of 
precursor HA0 into two disulfide-linked subunits, HA1 and HA2 (26). During maturation, 
HA molecules also homotrimerize into a rod like structure with a globular head and a 
stalk. The globular head accommodates the receptor binding site of the antigen. 
Although sialyloligosacharides on cell membranes, in general, are recognized by all HA 
subtypes, its host specificity somewhat depends on whether the sialic acid residue has a 
α-2,3 or α-2,6 linkage to galactose. While most avian and equine influenza viruses favor 
the N-acetylneuraminic acid α-2,3-galactose (NeuAcα2,3gal) linkage, human viruses 
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preferentially bind to the N-acetylneuraminic acid α-2, 6-galactose (NeuAcα2,6gal) 
linkage (27). Tracheal epithelial cells of pigs express both types of receptors which 
render them a suitable “mixing vessel” for generation of avian-human reassortant 
influenza viruses with pandemic potential (28). Once HA binds to its receptors on the 
cell membrane, the virions are endocytosed into intracellular endosomes. In the acidic 
pH of endosome, HA undergoes conformational changes to expose the N-terminal 
fusion peptide of the HA2 subunit which brings viral and endosomal membranes 
together to enable fusion (29). This membrane fusion allows release of viral RNP 
complex into the cytoplasm to be imported into the nucleus for replication.  
 
2.2.5. NP          
 The NP gene (1565 nucleotides) encodes a highly basic, single-strand RNA 
binding protein (MW 56.1 kDa) called nucleoprotein (16). NP encapsidates viral RNA 
molecules through their sugar-phosphate backbone to aid in their transcription and 
replication (30). Assembly of NP with viral RNA also provides structural organization to 
the RNP complex. This polypeptide contains at least two nuclear localization signals 
(NLS1, a.a. 3-13 and NLS2, a.a. 198-216) and thereby plays a decisive role in intracellular 
trafficking of RNP in and out of the nucleus (31, 32). NP also interacts with several viral 
and cellular proteins. In addition to self-oligomerization, NP binds to the viral 
polymerases (PB1 and PB2) and the matrix protein M1 (19, 33, 34). Cellular proteins that 
have, so far, been indentified to interact with NP include importin alpha, F-actin, CRM1, 
BAT1/UAP56 and Mx protein. Importin alpha, actin and CRM1 have functional 
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association with NP for cellular trafficking of RNP complex (35-37). On the other hand, 
UAP56 and Mx protein, through interactions with NP, up- and down-regulate viral RNA 
synthesis, respectively (38, 39).   
    
2.2.6. NA 
    The NA gene (1461 nucleotides) encodes for the second surface glycoprotein 
(MW 50 kDa monomer) of influenza virus, neuraminidase (16). The major function of 
this protein is enzymatic cleavage of sialic acids from cell surfaces to allow release of 
newly synthesized progeny virions. It cleaves the α-ketosidic linkage that binds terminal 
NeuAc5 to its sugar moiety (40). NA polypeptide is synthesized as a 454 a.a. monomer 
which oligomerizes to form a mushroom shaped tetrameric protein. The box shaped 
head contains the catalytic activity of the enzyme while the N-terminal stalk anchors it 
into the viral membrane (41). Apart from releasing progeny viruses, it also removes 
sialic acid residues from the carbohydrates on viral membrane glycoproteins to prevent 
virus self-aggregation (42). It has also been suggested to remove mucins to lower 
viscosity and allow the virus access to the epithelial cells. However, it does not play any 
role in attachment, replication or assembly of the virus (43). 
 
2.2.7. M 
 The M gene (1027 nucleotides) encodes two viral proteins: the matrix protein 
M1 (MW 27.8 kDa) and ion channel protein M2 (MW 11 kDa). M1 is the most abundant 
viral protein that underlies the lipid envelope to provide structural rigidity. It is also 
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believed to interact with the cytoplasmic tails of HA and NA (44). M1 binds to vRNPs 
through its C-terminal domain for their nuclear-cytoplasmic transport (45, 46). It also 
acts as a driving force for recruiting and assembling viral and host components during 
budding of the virus (47). The second protein, M2, is expressed from a spliced mRNA 
derived from M RNA segment. It is a type III integral membrane protein with a short 
ectodomain, a transmembrane domain and an endodomain or cytoplasmic tail (48). M2 
primarily functions as a tetrameric ion channel that allows influx of protons from the 
acidic endosome, leading to conformational changes and eventually uncoating of viral 
RNP complex (49).    
 
2.2.8. NS 
 The smallest gene, NS (890 nucleotides), also encodes two viral proteins: NS1 
(MW 26.8 kDa) and NEP (formarly NS2, MW 14.2 kDa). Although NS1 is not incorporated 
as a structural component into the virion, it is abundantly synthesized during virus 
replication. NS1 is a multifunctional protein which not only assists in viral replication but 
also defends against cellular anti-viral responses. It is synthesized as a 230-237a.a. long 
polypeptide which likely forms dimers (50). NS1 protein is known to interact with the 
viral replication complex (RNP) and its role has been suggested in replication of vRNA as 
well as selective enhancement of viral mRNA translation (51-53). NS1 protein is 
functionally divided into two domains: N-terminal RNA-binding domain (RBD, a.a. 1-73) 
and C-terminal effector domain (a.a. 74-230) (54, 55). The RBD can nonspecifically bind 
to dsRNA and thereby prevent activation of several transcription factors (NF-kB, IRF-3, 
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JNK/AP-1) required for IFN-α/ß induction (56-58). More recently, it has been shown 
that, RIG-I, a cytoplasmic sensor for pathogen associated molecular patterns like ssRNA, 
is also inhibited by NS1 to block interferon induction (59). The RBD of NS1 also plays a 
potential role in inhibiting another cytoplasmic, dsRNA binding antiviral protein: 2’-5’ 
oligoadenylate synthatase (OAS/RNaseL) (60). On the other hand, the effector domain 
of NS1 antagonizes the immune response at the post-transcriptional level through 
interaction with a number of cellular proteins. It can bind to two essential components 
of the cellular pre-mRNA processing machinery, namely, the 30 kDa subunit of cleavage 
and polyadenylation specificity factor (CPSF 30) and the poly (A)-binding protein II 
(PABPII); and this leads to accumulation of defective cellular pre-mRNAs (uncleaved or 
with short poly-A tail) in the nucleus of infected cells (61, 62). Interestingly, however, 
inhibition of CPSF30 by NS1 does not affect influenza virus mRNA processing since 
polyadenylation of influenza mRNA is independent of this cellular protein. The effector 
domain is also known to inhibit activation of serine/threonine protein kinase R (PKR), an 
anti-viral protein that can diminish viral protein synthesis (63). Finally, in an attempt to 
thwart the development of adaptive immune response, NS1 protein inhibits maturation 
and migration of dendritic cells leading to dysfunctional T cell stimulation and decreased 
cytokine production (64).  
The second protein, NEP (nuclear export protein), is expressed from a spliced 
mRNA of NS RNA segment and is present in virions in a phosphorylated form (65). The 
main function of this protein is, in association with M1, transport of viral 
ribonucleoproteins from the nucleus to the cytoplasm. A leucine/methionine rich 
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nuclear export signal in the N-terminus is thought to be vital for this function (66). As for 
the mechanism of nuclear export, NS2 protein has been shown to interact with several 
nucleoporins as well as the nuclear export receptor, Crm1 (66, 67). Recently, it has also 
been suggested to play a role in regulation of viral RNA transcription and replication 
(68). 
 
3. Replication cycle of influenza A virus 
 One complete replication cycle of influenza A virus can be divided into several 
stages: attachment, entry, fusion and uncoating, genome transcription, viral protein 
synthesis, assembly and egress/budding. Viral attachment to cell surface receptors 
(sialic acid) is mediated by hemagglutinin (HA) protein which has been described in 
section 2.2.4. Following attachment, virions are endocytosed into cellular 
compartments. Several endocytic mechanisms including clathrin-coated pits as well as 
clathrin-caveolin independent pathways have been described for influenza virus entry 
(69, 70). Low pH within the endosome brings about conformational changes in HA 
protein leading to fusion of viral and endosomal membrane resulting in release of viral 
RNP complex into the cytoplasm. Viral RNAs along with their replicases are then actively 
transported into the nucleus. Nuclear localization signals on the nucleoprotein are 
essential for this transport (31, 32). Once inside the nucleus, negative sense viral RNA 
segments are transcribed into mRNAs in a cap-dependent manner. These mRNAs are 
thereafter transported out into the cytoplasm for viral protein synthesis. Nucleoprotein 
(NP) and NS1 protein are preferentially synthesized at the early stage of viral infection 
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while synthesis of HA, NA and M1 is deferred to a later stage (71). After certain cycles of 
viral protein synthesis, the transcription machinery switches from mRNA to cRNA 
(complementary to viral genomic RNA) and vRNA (viral genomic RNA) synthesis. 
Following viral replication, RNP complexes are assembled in the nucleus and are 
exported out to the cytoplasm by M1 and NEP (46, 66). In the final step, the viral 
genome and proteins are assembled on the plasma membrane and newly synthesized 
virions are released from the apical surface of epithelial cells. 
 
4. Pathogenesis of influenza A virus 
 The outcome of influenza virus infection varies with different virus subtypes and 
the susceptible host. In wild aquatic birds which serve as the natural reservoir hosts for 
influenza, viral replication is largely restricted to the gastro-intestinal tract and the 
infection is generally asymptomatic (72). In other birds such as domestic poultry, turkey, 
quail and pheasant, influenza infection is normally non-fatal; with the exception of some 
highly pathogenic H5 and H7 subtypes, which have run havoc among chickens in recent 
years (73). In mammalian hosts (swine, equine, human), influenza virus is mainly a 
respiratory pathogen with disease severity ranging from asymptomatic to severe 
systemic fatal infection. The virus primarily infects and replicates in the ciliated 
columnar trachea-bronchial epithelium and then spreads to the lower respiratory tract 
or sometimes to systemic organs. Normal manifestations of the seasonal illness include 
fever, headache, cough, sore throat, anorexia and malaise. Pathogenesis of influenza 
virus, as described here, can mainly be ascribed to its ability to shut off host cell protein 
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synthesis, induce apoptosis and regulate several cellular transcription systems in order 
to avoid the host immune response. The PB2 polymerase protein, as mentioned in 
section 2.2.1., binds to host cell mRNA cap structures in the nucleus and cleaves them to 
prime viral mRNA synthesis (17). The decapped cellular mRNAs then get degraded. 
Nuclear export of cellular pre-mRNAs that escape “cap snatching” is blocked by NS1 
protein by inhibiting their splicing (74). Productive replication of influenza virus in 
respiratory epithelium results in apoptotic cell death (75). At least three viral proteins, 
NA, NS1 and PB1-F2, are known to regulate apoptosis of infected cells (22, 76, 77). 
Influenza virus infection activates several transcription factors which in turn induce 
expression of a number of anti-viral cytokines and chmokines genes. Viral NS1 protein, 
as explained in section 2.2.8., plays an important role in regulating those cellular 
transcription systems. The NS1 protein is a known antagonist of IFN α/ß production (56). 
It also inhibits maturation and cytotoxic T cell stimulation of dendritic cells and thereby 
stalls the development of an adaptive immune response against the virus (64). However, 
apart from these general mechanisms of cellular pathogenesis, highly virulent influenza 
viruses possess many other features to develop severe fatal disease.                  
Highly virulent human and avian influenza viruses, which have the potential to 
cause a human pandemic, exhibit several other pathogenic characteristics.  
Experimental infection of monkeys with virulent H5N1 influenza virus (human isolate) 
produces severe lesions including necrotic broncho-interstitial pneumonia, damaged 
respiratory epithelium and intra-alveolar hemorrhage as well as necrotic lesions in 
lymphoid organs, liver and kidney (78). Virulence of these viruses has been attributed to 
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several factors. One major determinant of influenza virus pathogenesis is the 
cleavability of precursor hemagglutinin protein (79). Proteolytic cleavage of precursor 
hemagglutinin (HA0) protein into two disulfide linked subunits, HA1 and HA2, is a 
prerequisite for successful fusion of viral and host endosomal membranes and therefore 
is necessary for viral infection. Low pathogenic avian influenza viruses and most 
mammalian influenza viruses except H7N7 equine influenza viruses, have a single 
arginine residue at the cleavage site between HA1 and HA2 subunits (80, 81). This 
requires serine family proteases for activation, therefore restricting their replication to 
the respiratory tract (82). On the other hand, highly pathogenic avian influenza viruses 
possess multiple basic amino acid residues at the cleavage site which is recognized by 
several ubiquitous proteases such as furin and PC6 (80, 83). This allows them to infect 
systemic organs other than lungs and thereby enhances their pathogenicity. Viral 
neuraminidase (NA) has also been suggested to play a role in it virulence. Lack of a 
carbohydrate side chain on NA in some viruses such as WSN/33 (H1N1) allows them to 
sequester cellular plasminogen which in turn facilitates the cleavage of hemagglutinin 
(84). The high replication ability of the 1918 pandemic influenza strain in cell culture in 
absence of trypsin has also been attributed to its neuraminidase protein (85). Another 
virulence factor and pro-apoptotic protein, PB1-F2, from this pandemic strain not only 
enhances the pathogenecity of the virus but also exacerbates the subsequent bacterial 
infections (Streptococcus pneumonia) by increasing cytokines and chemokines release 
(86). Additionally, the carboxy-terminus of the NS1 protein from highly virulent H5N1 
human isolates has been found to possess a PDZ binding motif (Glu-Ser-Glu-Val, ESEV) 
17 
 
which can interfere with cellular signaling pathways responsible for protein trafficking 
and maintenance of cell morphology (87). Pathogenesis of influenza virus is a 
profoundly studied field and several other viral and host factors are yet under 
investigation that may elucidate important aspects in the disease progression and 
virulence of this virus. 
 
5. Immune response to influenza A virus 
 In the wake of a seasonal influenza infection, an immune-competent host 
generates a robust anti-viral response. This anti-viral immunity consists of both innate 
and adaptive responses that enable containment and clearance of the viral infection in 
about a week’s period.    
 
5.1. Innate immune response 
 The innate immunity is a relatively non-specific response that constitutes the 
first line of defense against an invading pathogen. This defense mechanism is 
considered primitive as it has remained conserved among mammals, lower vertebrates 
and invertebrates. However, its does not provide a memory or long-lasting protection. 
The innate immune system is comprised of physical barriers, soluble chemical factors 
and cellular components. 
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5.1.1. Physical barriers 
 The epithelial surfaces form the first physical barrier to any bacterial or viral 
infections. Mucins produced by respiratory epithelial cells trap bacteria or virus particles 
while movement of broncho-pulmonary cilia clears them out of the airway.  
 
5.1.2. Soluble antimicrobial mediators 
Pathogens that successfully breach this barrier are neutralized by soluble 
antimicrobial factors, such as lysozyme, lactoferrin and defensins. Human alpha-
defensins, for instance, are short cationic antimicrobial peptides of neutrophils that can 
inhibit influenza virus replication (88). Another well characterized heat liable, enzymatic 
mediator of the innate immunity is the complement system. Its antimicrobial activity is 
primarily mediated through opsonization which activates neutrophils and mast cells to 
phagocytose and lyse complement bound pathogens. Its important role in anti-viral 
immunity was established when complement deficient mice were found to be more 
susceptible to influenza virus infection (89). Complement present in human serum can 
neutralize influenza virus and in vivo experiments show that in association with natural 
antibody (IgM), complement can provide protective immunity in influenza naïve hosts 
(90-92). 
 
5.1.3. Pattern recognition receptors 
 The innate immune system maintains an evolutionarily preserved set of 
receptors that distinguishes self from non-self (microbial) antigens based on their highly 
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conserved structural features called pathogen associated molecular patterns (PAMPs). 
PAMPs can consist of sugar moieties, lipids, nucleic acids or combinations of any of 
these. The receptors that recognize them are, therefore, known as pattern recognition 
receptors (PRRs).  
 Collectins, the C-type lectin bearing members of the collagen family, are 
important soluble PRRs of the innate immune system. Among the nine members that 
have been identified so far, mannan-binding lectin (MBL) and surfactant proteins A and 
D (SP-A and SP-D) are the most studied for their role in host defense against infectious 
agents. MBL is secreted into the bloodstream mainly by the liver whereas SP-A and SP-D 
are predominant among alveolar spaces in the lung (93, 94).  They, in general, bind to a 
variety of carbohydrate residues on pathogen surfaces and thereby activate cells to 
respond by way of agglutination, complement activation, opsonization and phagocytosis 
(95, 96).  During influenza infection, human MBL can bind to both HA and NA on virus 
particles and thereby neutralize and contain the viral spread (97). Similarly, the 
protective mechanism of SP-A and SP-D in influenza infection involves direct virus 
neutralization, opsonization or enhanced uptake and hydrogen peroxide production by 
neutrophils (98, 99). 
 In the past decade, scientific knowledge about cellular sensing of a microbial 
invasion was revolutionized by the discovery of toll-like receptors (TLRs). The first toll 
protein was identified in Drosophila as a mediator of its antifungal immunity (100). This 
was soon followed by the characterization of its mammalian homologue in humans, 
hToll or currently recognized as TLR4 (101). Since then 13 receptors (TLR 1 -13) have 
20 
 
been discovered in mammals. Among them, TLR10 is expressed in humans but not 
mouse whereas TLR11 has only been found in mouse. Except for TLR3, 7, 8 and 9 which 
are found within endosomes, all others are expressed on the plasma membrane (102). 
All of these TLRs are type-I transmembrane glycoproteins with a leucine rich 
extracellular domain and a cytoplasmic domain containing toll/interleukin-1 receptor 
(TIR) homology. The extracellular structure binds to its respective ligands and the 
intracellular domain is responsible for passing on the activating signal downstream 
(103). TLR2 which forms heterodimers with TLR1 and TLR6 binds to tri- or diacylated 
lipopeptides respectively. TLR3 recognizes dsRNA molecules while lipopolysaccharide 
(LPS) acts as a ligand for TLR4. Bacterial flagellin binds to TLR 5. TLR7 and 8 primarily 
sense viral ssRNA molecules whereas unmethylated CpG containing bacterial DNA 
motifs bind to TLR9. Uropathogenic bacteria can be detected by TLR11. Specific ligands 
for TLR10, 12 and 13 have not been identified yet (102). Binding of specific microbial 
components to TLRs results in their activation. All of these receptors use a common 
signaling pathway. Following recognition of a microbial motif, toll like receptors form 
dimers – most of them form homodimers, but TLR2 uses TLR1 or TLR6 to form 
heterodimers. Based on the adaptor molecules used, their signaling pathways are 
generally classified into two categories: (a) MyD88 dependent pathway and (b) MyD88 
independent pathway. All but TLR3 utilize the MyD88 dependent pathway to activate 
transcription factor NF-kB which in turn leads to expression of various inflammatory 
cytokine genes. On the other hand, TLR3 and in part TLR4 activation promotes 
expression of interferon genes through stimulation of a different transcription factor 
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called IRF3. However, activation of either pathway results in production of pro-
inflammatory cytokines and IFN which in turn lead to the development of antigen 
specific adaptive immunity (104). TLR7 expressed on plasmacytoid dendritic cells can 
detect influenza virus genomic RNA (105). Similarly, TLR3 which is constitutively 
expressed in pulmonary epithelial cells mediates activation and production of cytokines 
during influenza virus infections (106). More recently, an important role of the TLR7-
MyD88 signaling pathway has been suggested even for the development of a virus 
specific adaptive (CD8 + T cell) immune response (107). 
 While TLRs are efficient at detecting pathogens either on cell surfaces or inside 
endosomes, some other recently identified PRRs can sense PAMPs in the cytosol: RIG-1 
(retinoic acid inducible gene -1), MDA-5 (melanoma differentiation associated gene -5), 
NOD-1/2 (nucleotide binding oligomerization domain-1/2) and other C-type lectins e.g. 
dectin-1 [reviewed in (108, 109)]. Although both RIG-1 and MDA-5 recognize dsRNA 
from viruses, RIG-1 was found to play a more important role in interferon signaling 
during influenza virus infection (110). Similarly, NLRs (NOD like receptors) can also 
recognize viral RNA and are necessary for activation of inflammasomes (multiprotein 
complex responsible for activation of inflammatory processes) as well as development 
of adaptive immunity (111, 112). 
 
5.1.4. Cells of innate immune system 
 Cells of monocytic lineage such as macrophages, dendritic cells and natural killer 
cells constitute the cellular compartment of innate immune system. 
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5.1.4.1. Macrophages 
 Macrophages are important effector cells of the innate immune system. In 
steady state or inflammation, circulating monocytes differentiate to generate tissues 
macrophages. Depending upon their anatomical localization, macrophages have been 
given different names, for example, alveolar macrophages in the lungs, microglia in the 
CNS, Kupffer cells in the liver etc (113). These are very potent phagocytic cells and their 
primary function is maintenance of tissue homeostasis by clearing out cellular debris, 
apoptotic as well as necrotic cells. However, upon activation, they produce large 
amounts of inflammatory cytokines and chemokines. Alveolar macrophages have been 
found susceptible to influenza virus infection in vitro and the infection results in quick 
cytopathic death of these cells (114). Influenza infected macrophages show an increased 
transcription level for an array of anti-viral cytokines including IL-1 beta, IL-6, TNF-alpha 
and IFN α/ß (115). They also produce chemokines such as RANTES, monocyte 
chemotactic protein -1 (MCP-1) and macrophage inflammatory protein -1 alpha (MIP -
1α) which further attract more mononuclear cells to the site of infection to aid in viral 
clearance (116). 
 
5.1.4.2. Dendritic cells 
 Dendritic cells (DC) are a unique population of cells that play a pivotal role in 
molding immune responses against invading pathogens. These are a sparsely distributed 
heterogeneous population of hematopoietic leukocytes with diverse phenotypes and 
functions. In 1973, R. M. Steinman and Z. A. Cohn first observed a population of large 
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stellate cells with distinct morphological properties in mouse spleen and described 
them, due to their veiled structure, as “dendritic cells” (117). Apart from lymphoid 
organs (spleen, lymph nodes), DCs are also found in non-lymphoid tissues such as lungs, 
epidermis (langerhan’s cell), dermis (interstitial cell) etc. Some characteristic features of 
DCs are: [a] DCs are plastic adherent, low density cells with poor viability in culture. [b] 
They have few lysosomes and lack Fc receptors. [c] They are the most potent antigen 
presenting cells (APC) and efficient activators of T lymphocytes. A very small number of 
DCs pulsed with little amount of antigen can stimulate a large number of T cells. They 
can stimulate proliferation of both CD4+ and CD8+ T lymphocytes (118). 
 Because of their heterogeneity, the origin of DCs has been a highly debated topic 
in recent years (Figure 1.1). In the bone marrow, DCs can originate from either Flt3+ 
(FMS like tyrosine kinase 3) common myeloid (CMP) or common lymphoid progenitor 
(CLP) cells (119, 120). CMPs and CLPs differentiate into macrophage-DC progenitors 
(MDP, Flt3+M-CSFR+CX3CR1+) and common DC progenitors (CDP, Flt3+CD115+) 
respectively which enter into the bloodstream and later migrate into secondary 
lymphoid organs to give rise to DCs. However, in the periphery during inflammation or 
infection, monocytes can also differentiate to generate inflammatory DCs (121). In 
human and mouse, based on phenotypic surface markers expressed and specialized 
functions, DCs have been categorized into several sub-types. Broadly, in lymphoid 
tissues, DCs are often classified as either conventional DCs (cDC), potent antigen 
presenting cells or plasmacytoid DCs (pDC), producers of type I interferon (122). 
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Figure 1.1: DC ontogeny in mice. 
                                                  Reproduced with permission from Nature Immunology 8, 1199-1201 (2007) 
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Immediately after differentiation from hematopoietic precursors, DCs circulate 
throughout the periphery in “immature” forms and scan the body for any self antigen 
(tolerance) or invading pathogens (immunity). Once encountered, highly adept 
“immature” DCs capture the antigen by macropinocytosis, phagocytosis or receptor 
mediated endocytosis (123). This antigen capture initiates a series of phenotypic and 
biochemical changes in DCs called “maturation”. Maturation of DCs is characterized by 
reduced antigen capturing ability, increased surface expression of co-stimulatory 
molecules, i.e. CD68, CD83, CD86, MHC I, MHC II and production of cytokines and 
chemokines. Activation of the Interferon signaling pathway by microbial PAMPs has 
been shown to stimulate this maturation process (124). Initiation of maturation drives 
DCs to migrate to secondary lymphoid organs where they present the captured antigens 
to lymphocytes for proliferation and functional activation.  Depending on the invading 
pathogen, DCs can present antigen on either MHC I or MHC II to a particular subset of 
lymphocytes. For intracellular microbes like viruses, DCs present antigens on MHC I 
which is recognized by CD8+ T cells. This results in vigorous proliferation of cytotoxic T 
cells that can in turn lyse infected cells. On the other hand, extracellular pathogens are 
taken up into endosomes from where they are presented on MHC II molecules leading 
to CD4+ T cell mediated immune response (125). While peptides mounted on MHC 
molecules provide the “signal 1” to T cells, “signal 2” or “co-stimulation” is delivered by 
interactions of CD80/86 with CD28 on T cells. Signal 3, a term coined very recently, is 
used by dendritic cells to promote T cell differentiation into specific effector cells, e.g. 
cytotoxic or Th1 or Th2 cells (126). Polarization of Th1 or Th2 type immunity is 
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determined by pathogen primed DCs through production of several DC derived 
polarizing factors. IL-12 primarily is considered to be the Th1 type cytokine whereas IL-4 
(in absence of IL-12) drives helper cells towards Th2 type immunity (127). Th2 cells 
synthesize IL-5 and IL-4 which in turn stimulate B cells to produce appropriate 
antibodies against the invading pathogen. 
Equine dendritic cells, when cultured in vitro from blood monocytes with GM-
CSF and IL-4, exhibits similar morphological and cytochemical characteristics as of 
human DCs (128). They express similar pattern of phenotypic surface makers as human 
DCs and are also potent stimulators of T cells as observed in mixed lymphocyte 
reactions (129). When activated by maturation stimuli such as inactivated E.coli, 
immature equine DCs can mature; express maturation markers on their surface and 
produce enhanced cytokines as well (130).   
 The pivotal role of DCs in the innate and adaptive immune response makes them 
a major target for bacteria, viruses and other pathogens. Although the in vivo role of 
DCs in influenza infection is not completely understood, several in vitro studies have 
helped in unraveling some of the mysteries. It is not known whether influenza naturally 
infects DCs in vivo. However, ex vivo generated DCs of both human and mice origin can 
be successfully infected by influenza viruses (131, 132). However, the infection is non-
productive – despite the synthesis of viral proteins, little progeny virus is produced. The 
infection is also non-toxic as infected DCs do not show any cytopathic effect or 
apoptosis (131). Influenza virus infected DCs can initiate a strong proliferation of 
cytotoxic CD8+ T lymphocytes (133). Activated DCs also secrete antiviral cytokines (IFN 
27 
 
α/ß) and promote a Th1 type immune response by stimulating IFN γ production by CD4+ 
T cells (134). The NS1 protein of influenza virus, as mentioned earlier, has been shown 
to inhibit the maturation of infected immature DCs and thereby prevent development of 
an adaptive immune response (64).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
Table 1.2: CD antigens. 
CD antigen Cellular expression Functions Expression on 
DC 
CD1b 
(CD1w2 homolog) 
Cortical thymocytes, 
Langerhans cells, 
Dendritic cells 
Antigen (lipid) 
presentation 
+ 
CD4 Thymocyte subsets, 
TH1 and TH2 cells, 
monocytes, 
macrophages 
Co-receptor for MHC 
class II molecules 
+/- 
CD8 Thymocyte subsets, 
cytotoxic T cells 
Co-receptor for MHC 
class I molecules 
+/- 
CD11c Myeloid cells Binds fibrinogen ++ 
CD14 Myelomonocytic cells Receptor for LPS and 
LPS binding protein 
- 
CD86 Monocytes, activated B 
cells, dendritic cells 
Ligand for CD28 and 
CTLA4 
+ 
CD172a Myeloid cells Adhesion molecule +++ 
MHC I Nucleated cells Antigen presentation ++ 
MHC II T cells, B cells, 
macrophages, dendritic 
cells 
Antigen presentation ++ 
                                                                                  Adapted from Janeway’s Immunobiology, 7th ed. 
                                                                                                              J. Exp. Med. Vol. 179 April 1994, 1109-1118 
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5.1.4.3. Natural killer cells 
 Natural killer (NK) cells are a population of large granular lymphocytes that are 
particularly adept at lysis of target cells without prior sensitization. They are found 
abundantly in blood, liver, spleen, lymph nodes and other non-lymphoid organs such as 
pregnant uterus. They circulate in the body as “resting” cells containing a pool of 
constitutively expressed high levels of IFN γ, perforin and granzyme B mRNA transcripts 
(135, 136). However, these “resting” cells require activation by IFNα/ß or other pro-
inflammatory cytokines (IL-2, IL-12, IL-15 and IL-21) to acquire their cytolytic effector 
functions (137). Following activation, they produce an array of cytokines (TNF-α, IFN-γ 
etc.) and cytolytic mediators (perforins, granzymes). Activated NK cells kill target cells 
either by creating pores on membranes with perforins and granzymes or by activating 
apoptotic signaling in the target cells (137).  Since these naturally primed killer cells are 
broadly reactive and have the potential to kill harmful target cells as well as naïve host 
cells, their activity is strictly regulated through a series of activation and inhibitory 
receptors (138). The importance of NK cells in the innate immunity against influenza 
virus is evident by the large number of these cells that accumulate in the lungs of 
infected mice and any depletion or mutation of NK cell receptors can seriously 
exacerbate the illness (139, 140). NK cells recognize influenza HA proteins through direct 
interactions with its receptors called NKp46 and NKp44 (141, 142). Recent studies have 
also shown that use of an adjuvant that activates NK cells can boost the immunogenicity 
and protective efficacy of influenza vaccines (143). 
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5.1.5. Cytokine system 
 Cytokines are a diverse family of small proteins that are produced in response to 
different stimuli and exert their functions through binding of specific cellular receptors. 
They play an important role during viral infections. 
 Interferons are a type of cytokine that are produced during viral infections and 
are aptly named so because of their ability to interfere with viral replication. IFN-α and 
IFN-ß are type I interferons whereas IFN-γ is often called as type II. Although most 
nucleated cells can produce type I interferons, plasmacytoid DCs (pDCs) are considered 
as the specialized producers of these cytokines (144). They bind to a common cell-
surface interferon receptor and activate transcription of several genes (ISG, interferon 
stimulated genes) through Janus family tyrosine kinase pathway. Several protein 
products of ISGs have anti-viral activities. For example, oligoadenylate synthetase (OAS) 
helps in degradation of viral RNA while protein kinase R (PKR) has an inhibitory effect on 
viral protein synthesis. Another ISG protein, Mx is associated with resistance against 
influenza infection (145). On the other hand, IFN-γ is primarily produced by T cells and 
NK cells and its function is to activate macrophages. 
 Interleukins (IL) constitute another group of cytokines that are mainly produced 
by leukocytes. A number of interleukins have been identified so far which can act locally 
or systemically to exert divergent effects on both innate and adaptive immune 
responses. Some of them such as IL-1, -6 and -12 act as “pro-inflammatory” cytokines 
whereas IL-10 exhibits an “anti-inflammatory” activity. They bind to their specific 
receptors and activate the JAK-STAT signaling pathway to modulate cellular functions. 
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5.2. Adaptive immune response 
 The adaptive immunity is an antigen-specific, cellular defense system that 
requires activation by the innate immunity to eliminate a microbial infection. Although it 
develops late into an infection, it can provide a strong memory or lasting protection 
against the same invading pathogen. The adaptive immune system is predominantly 
comprised of T and B lymphocytes. 
 
5.2.1. T cells 
 T lymphocytes constitute an important effector arm of the adaptive immune 
response. Precursors of T lymphocytes develop from hematopoietic stem cells in the 
bone marrow and then migrate to the thymus for complete maturation (146). During an 
infection, APCs circulating in the periphery capture the antigen and bring them to the 
thymus where they present the antigen to T cells which in turn undergo “clonal 
expansion” to produce large numbers of progeny T cells. Depending on the surface 
molecule expressed on them, activated T cells perform different tasks to eliminate the 
invading pathogen. 
 
5.2.1.1. CD8+ T cells 
 Antigens presented on MHC class I molecules can be recognized by CD8+ T cells. 
Once activated, they become cytotoxic T lymphocytes (CTL) which are programmed to 
kill infected cells. Several mechanisms including calcium dependent perforin exocytosis 
and Fas mediated apoptosis have been suggested as the means by which CTLs destroy 
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infected cells (147). During influenza infection, CTLs play a critical role in viral clearance. 
Initial activation of naïve CD8+ T cells in lymph nodes occurs within the first 3 days of 
infection. Antigen primed CD8+ T cells thereafter start to divide, acquire their cytotoxic 
activity and exit through draining lymphatic vessels to reach the lungs (148).  Six days 
post infection, almost 70 % of lung-infiltrating lymphocytes are found to be cytotoxic. 
Most (90%) of these CTLs can recognize epitopes from either HA or NP viral protein 
(149). Viral antigen stimulated CTLs produce large amount of IFN-γ and TNF-α which 
help in recruiting leukocytes to the site of inflammation (148). Following viral clearance, 
memory CTLs down-regulate transcription of cytotoxic proteins and circulate in 
lymphoid (spleen) and non-lymphoid (skin/lungs) tissues (150). However, when re-
exposed to the same antigen, memory CTLs can rapidly initiate their cytotoxic functions 
(151). 
 
5.2.1.2. CD4+ T cells 
 CD4+ T lymphocytes are often referred to as helper T (T h) cells as their primary 
function is to assist B lymphocytes in producing antibodies against microbial infections. 
These T lymphocytes recognize antigens presented on MHC class II molecules and 
depending on the type of pathogen, they can differentiate into either Th1 or Th2 
phenotype. Th1 type CD4+ T cells produce IFN-γ and TNF-α, and stimulate cytotoxicity of 
macrophages and CTLs; whereas Th2 type cells secrete IL-4 and IL-5 and promote 
neutralizing antibody production by B cells (152). Influenza virus infection activates DCs 
to produce IL-12 which in turn drives CD4+ T cells towards Th1 phenotype. During 
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influenza virus infection, CD4+ T cells provide protection in a B cell dependent manner, 
although they themselves possess some cytotoxic (perforin) activity too (153). CD4+ T 
cells are also necessary for optimal recruitment of CD8+ T cells to the infected lungs and 
subsequent viral clearance by CTLs (154). Following recovery or live virus clearance 
activated CD4+ T cells progress to become memory cells. However the number of CD4+ 
memory T cells decline much faster than their CD8+ counterparts (155). 
 
5.2.2. B cells 
 B cells are a lymphocyte subpopulation responsible for eliciting the humoral 
immune response during an infection. In mammals, B cells originate in the bone marrow 
and mature in secondary lymph nodes or spleen. Terminally differentiated B cells are 
called plasma cells whose primary function is to produce antibodies to specific antigens 
(156). However, they can also uptake, process and present antigens to T cells in an MHC 
restricted manner (157). Neutralizing antibodies produced by B cells during an influenza 
infection have an important protective role and are therefore the main targets of 
vaccine induced immunity. Development of humoral immunity to an influenza infection 
consists of an early rise in IgM antibody titer followed by their affinity maturation and 
immunoglobulin class-switing to IgG, IgA and IgE antibodies (158). Mice that are 
deficient in B cell and therefore incapable of producing are 50 – 100 times more 
susceptible to a lethal influenza infection and they show a higher mortality rate when 
challenged with a pathogenic PR8 strain of influenza (159, 160). On the other hand, 
passive transfer of HA-specific antibodies to SCID mice can protect them for an influenza 
34 
 
infection (161, 162). These experiments clearly suggest the significant contributions of B 
cells and anti-viral antibodies in recovery from an influenza infection. Following 
exposure to an influenza infection, two compartments of memory B cells develop. One 
subset is comprised of long lived plasma cells or antibody secreting cells (ASC) that 
localize in the bone marrow and continuously generate antibodies to maintain an 
optimal level of plasma antibodies for protection against re-infection. The other 
compartment is populated with quiescent memory B cells that localize in lymphoid 
tissues or lungs and require stimulation by a recall antigen to divide and differentiate 
into ASCs (163).  
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6. Research objectives 
 In the past decades, DCs have been the subject of extensive research because of 
their versatile role in organizing the immune system both in health and illness. An array 
of both endogenous (interferon, interleukin) and exogenous (bacterial, viral pathogens) 
agents have been investigated for their role in the induction or inhibition of DC 
maturation (164, 165). However, little is known about what dictates the differentiation 
of DCs from bone marrow progenitor cells or monocytes. It is plausible to presume that 
the local cytokine milieu plays a critical role in this process. In vitro, GM-CSF and IL-4 are 
widely used to facilitate generation of DCs from monocytes, whereas other cytokines 
e.g. IL-10 and IL-6 can block this differentiation pathway (166-169). Knowledge about 
the effects of microbial infections on this differentiation process is still limited. 
 Recently, a body of accumulating evidence suggests that during infection or 
inflammation, DCs differentiate more readily from monocytes than from bone marrow 
precursor cells (170, 171). Preferential production of monocyte chemo-attractant 
proteins over neutrophil chemo-attractant proteins has also been reported during 
influenza infection (172). The number of monocytes that migrate to the respiratory 
mucosa overwhelmingly exceeds the number of DCs (173). These findings underscore 
the importance of monocytes in the replenishment of APCs in airway mucosa during 
influenza infection. Therefore, it was hypothesized that virus-mediated impairment of 
monocyte differentiation into DC may contribute to influenza virus pathogenesis and 
also to evasion of host immune responses. Equine influenza viruses were used in an 
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equine monocyte model to determine the effects of the viral infection upon the 
differentiation of monocyte-derived DCs. 
 To test the experimental hypothesis, three specific aims were investigated: 1. 
Determination of the ability of equine influenza viruses to infect and replicate in equine 
monocytes when cultured in the presence of both eq.GM-CSF and eq.IL-4 for 
differentiation into DCs. 2. Characterization of morphologic, phenotypic and functional 
alterations of equine influenza virus infected monocytes with respect to their capability 
to differentiate into DCs. 3. Determination of the role of virus subtype and influenza NS1 
protein in the virus mediated inhibition.   
The experimental approaches that were used for evaluating aforementioned 
specific aims are as follows. In specific aim 1, the ability of equine influenza virus to 
replicate in equine monocytes was investigated by assessing the transcription of viral 
genomic RNA in infected monocytes and also by measuring viral protein (NP) synthesis 
and progeny virus production. Cytotoxicity of the virus was determined by its ability to 
induce apoptosis in infected cells. For specific aim 2, influenza virus infected monocytes 
were first evaluated microscopically for their morphologies and then analyzed by flow 
cytometry for phenotypic expression of DC surface markers. Functional inhibition due to 
the viral infection was measured by the endocytic ability and cytokine production by 
infected monocytes. Finally, the role of virus subtype and influenza NS1 protein in this 
process was examined in specific aim 3 by employing an H3N8 virus and another NS1-
truncated virus. 
Copyright © Saikat Boliar 2009 
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CHAPTER II 
MATERIALS AND METHODS 
 
 
Purification of equine monocytes from PBMC 
 Isolation of equine monocytes from peripheral blood mononuclear cells (PBMC) 
and further culture for differentiation into DCs was carried out according to a previously 
published method (129). Horses were randomly selected from a population maintained 
at the University of Kentucky Maine Chance Farm and screened for presence of serum 
antibody against a panel of equine influenza viruses. A group of influenza sero-negative 
horses (n = 10, of mixed breed, age and sex) were finally selected for all future 
experiments. Briefly, blood was collected in heparin containing tubes or bottles and was 
placed at room temperature for 30 min for clear separation of plasma from red blood 
cells. PBMCs were isolated from this heparinized blood by Ficoll-Paque density gradient 
centrifugation. Blood plasma including the Buffy coat was carefully layered onto 10 ml 
of Histopaque – 1077 (Sigma Aldrich) in 50 ml conical tubes (Corning) and was 
centrifuged at room temperature (22°C) at 400g for 30 min without brakes (Beckman 
GS-6KR centrifuge, rotor type GH-3.7). A creamy white band of PBMCs that appeared at 
the interface between the plasma and Histopaque – 1077 was collected and washed 
twice with PBS (BioWhittaker, pH 7.4) by centrifugation at 500g for 5 min. PBMCs were 
then suspended in complete RPMI medium (cRPMI; RPMI-1640 containing 10% 
autologous horse serum, 2mM L-glutamine, 55μM ß–mercaptoethanol, 100 U/ml 
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penicillin-streptomycin and 0.25μg/ml amphotericin B) at a density of 107 cells per ml 
and plated in 100 mm tissue culture treated plates. For the autologous serum used in 
cRPMI medium, blood was collected in 10 ml tubes (BD vacutainer™), incubated at 37°C 
for 30 min and then centrifuged at 900g for 10 min. After 4 hrs of incubation at 37°C 
with 5% CO2, non-adherent cells (mainly lymphocytes) were removed by gently washing 
the plates twice with warm PBS. In a few occasion, adherent cells were stained for CD14 
(Big 10, Axxora Platform) and examined by flow cytometry (FACScan, Becton Dickinson) 
to determine the purity of monocytes among adherent cells. 
 To stimulate differentiation into DCs, purified monocytes were further cultured 
in cRPMI medium supplemented with eq.GM-CSF and eq.IL-4 (CHO cell supernatants 
containing recombinant eq.GM-CSF and eq.IL-4 were added at 10% each) at 37°C with 
5% CO2 for 4 days. 
 
Preparation of virus stock 
 Equine influenza viruses that were used for different experiments are: (1) 
Influenza A/equine/New York/49/73, (H7N7 subtype); (2) Influenza 
A/equine/Kentucky/5/02, (H3N8 subtype) and (3) Influenza A/equine/Kentucky/5/02 
NS1-73, a carboxy-terminally truncated virus (a kind gift from Dr. Peter Palese, Mount 
Sinai School of Medicine). The Kentucky/5/02 NS1-73 is a recombinant H3N8 subtype 
virus that expresses only the N-terminal 73 amino acid residues out of the full 219 
amino acid long NS1 protein (174). Wild type viruses (NY/73 and KY/02, virus repository, 
OIE equine influenza reference laboratory, University of Kentucky) were propagated in 
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pathogen free 10-day-old embryonated chicken eggs whereas immune-incompetent 7-
day-old eggs were used for the recombinant virus (KY/02 NS1-73) since this virus lacks 
proper anti-interferon activity. Viruses (0.1 ml per egg, 1:1000 dilutions in PBS) were 
inoculated into allantoic cavities and then incubated at 37°C for 72 hrs. Allantoic fluids 
were harvested and then clarified of any egg debris by centrifugation. Titration of the 
stock virus was done by 50% egg infectious dose (EID50) assay as described by Reed and 
Muench (175). Stock virus was stored in 1 ml aliquots at – 80°C. 
 Where needed, viruses were inactivated by UV irradiation using a UV Stratalinker 
1800 (Stratagene). Briefly, a thin layer of 1 ml virus was poured into a 35 mm plate, 
placed on ice and irradiated at 254 nm for 30 min at a distance of 10 cm. Proper 
inactivation was confirmed by inoculation of 0.1 ml of irradiated virus into a 10-day-old 
embyronated chicken egg. Although UV irradiated viruses could not replicate, they 
retained their receptor binding (cell attachment) capability as they could agglutinate 
chicken RBCs in the hemagglutination (HA) assays. 
 
Infection of equine monocytes with equine influenza virus 
 Before infection, monocytes were washed twice with PBS to remove serum. The 
virus stock was diluted in serum free infection medium (cRPMI with 0.25 % bovine 
serum albumin replacing 10 % autologous horse serum plus 1μg/ml TPCK trypsin). 
Monocytes were infected with an infectious dose of approximately 5 EID50 units per cell 
or an equivalent amount of UV inactivated virus. Mock inoculums consisted of only the 
infection medium. After 1 hr of adsorption at 37°C, viral inoculums were removed; cells 
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were washed twice with PBS and then cultured in cRPMI medium with 1μg/ml TPCK-
trypsin for 4 days or as otherwise mentioned. 
 
Quantification of viral RNA levels in infected cells 
 To determine whether equine monocytes cultured in the presence of eq.GM-CSF 
and eq.IL-4 can support replication of equine influenza virus, viral genome transcription 
in infected cells was measured by relative real-time PCR assay. Purified equine 
monocytes were plated at 106 cells per ml and incubated overnight in cRPMI 
supplemented with eq.GM-CSF and eq.IL-4. The next day, cells were infected with 
equine influenza virus as described earlier. Following infection, cell samples were 
collected at different time points post-infection (p.i.) e.g. 0, 4, 8, 12 and 24 hrs. Total 
cellular RNA was extracted from collected samples using the RNeasy Mini Kit (Qiagen) 
following manufacturer’s instructions. Possible DNA contamination was eliminated by 
in-column treatment with DNase I (RNase free DNase set, Qiagen). Taqman® one-step 
RT-PCR master mix reagents (Applied Biosystems) and an ABI Prism 7500 fast real-time 
PCR system (Applied Biosystems) were used to perform the assay. Five micrograms of 
extracted RNA were added to a total reaction volume of 20μl in a 96 well plate (Applied 
Biosystems). Primers and probe (TaqMan MGB), used in this experiment, were designed 
to amplify a 63bp region of the NP gene. The program for amplification consisted of a 30 
min period at 48°C, then 10 min at 95°C followed by 40 cycles with the following 
conditions: 95°C for 15 sec and 60°C for 1 min. Threshold cycle (Ct) values of respective 
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samples were normalized by comparison with the ribosomal protein large PO (RPLPO) 
RNA level. 
EqFlu NP forward primer:           5’- GAAGGGCGGCTGATTCAGA -3’ 
EqFlu NP reverse primer:           5’- TTCGTCGAATGCCGAAAGTAC -3’  
EqFlu NP probe:                          5’- CAGCATAACAATAGAAAGGA -3’  
    
Quantification of viral protein synthesis in infected cells 
 Viral protein synthesis in infected monocytes was quantified by detecting NP 
protein levels using flow cytometry. Following infection of monocytes, samples were 
collected at 5 different time points p.i. (0, 4, 8, 12 and 24hrs). Cells were washed twice 
with PBS and then fixed with 2% paraformaldehyde in PBS for 1 hr at room temperatute. 
Cellular permeabilization was achieved by incubating samples in 0.5% saponin, 5% FBS 
in PBS solution for 15 min at 4°C. After washing twice with PBS, cells were first stained 
with the primary antibody (Mouse influenza A anti-NP, clone # M2110169, Fitzgerald 
Industries International Inc.) and then with a FITC-conjugated secondary antibody 
(Immunopure goat anti-mouse IgG, F(ab’)2, Pierce) at 37°C for 30 min each (1 μg of Ab 
per 106 cells). Subsequently, all samples were washed twice, resuspended in 400μl FACS 
buffer (PBS with 1% BSA and 0.1% sodium azide) and analyzed with by flow cytomerty 
(FACScan, Becton Dickinson) for their respective mean fluorescence intensities (MFI). 
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Detection of apoptosis in virus infected monocytes 
 Influenza virus infected or mock inoculated monocytes were further cultured in 
cRPMI medium with eq.GM-CSF and eq.IL-4 for 4 days. On day 4 p.i., cells were 
collected, washed in PBS and then resuspended in Annexin V binding buffer at the rate 
of 106 per ml. Next, 105 cells were used for staining with Annexin V and propidium 
iodide (PI) according to manufacturer’s instructions (Annexin V-FITC apoptosis detection 
kit I, BD Pharmingen). After 15 min of incubation at room temperature, cells were 
analyzed by flow cytometry. When cells start to undergo apoptosis, phosphatidylserine 
(PS), a membrane phosphor lipid, translocates from inside to the outer side of the 
membrane. Annexin V then binds to PS on apoptotic cells in a calcium dependent 
manner. PI is used to separate viable cells from the non-viable ones. 
 
Analysis of cell count, viability and average diameter 
 Vi-Cell TM (Beckman Coulter), an automated cell viability analyzer, was used to 
determine total cell counts, percent of viable cells and their average diameters. Briefly, 
cells were diluted in PBS at 1:10 ratio and then were run through the analyzer using the 
program specific for PBMC. This automated machine uses trypan blue exclusion method 
and video imaging to determine cell viability as well as the average diameter of the cells. 
 
Analysis of cell surface marker expression by flow cytometry 
 Levels of expression of different cell surface markers for DC on mock- or 
influenza infected cells were examined by flow cytometry (176). On day 4 p.i., cells were 
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collected, washed twice with PBS and then resuspended in FACS buffer (PBS 
supplemented with 1.0% BSA and 0.1% sodium azide). Pre-incubation with purified 
horse IgG (ChromPure horse IgG, Jackson ImmunoResearch) for 30 min was used to 
block non-specific binding through Fc receptors. Cells were then incubated with either 
primary or fluorochrome-conjugated antibodies (1 μg of Ab per 106 cells) for 30 min at 
4°C. The following antibodies were used: CD172a (DH59B, VMRD), CD1w2 (MCA2058PE, 
AbD Serotec), CD86 (IT2.2, Biolegend), MHCI (CVS22) and MHCII (CVS10, both CVS mAbs 
were gifts from Dr. Paul Lunn, University of Colorado). After labeling with primary 
antibodies, cells were washed twice with FACS buffer and then stained with FITC labeled 
secondary antibodies for 15 min at 4°C. Isotype-matched antibodies (BD Pharmingen) 
were used as negative controls. Cells were fixed with 2% paraformaldehyde in FACS 
buffer and then analyzed via flow cytometry (FACScan, Becton Dickinson). Cells were 
gated based on forward- and side-scatter profile and data were analyzed using 
CellQuest TM software. 
 
Quantification of cellular gene expression by real-time PCR  
 Cellular gene expression levels were quantified by two-step real-time PCR assays 
(RT-PCR). Total cellular RNA was extracted from infected cells with RNeasy Mini kit 
(Qiagen) as described earlier in this chapter. Then, following manufacturer’s 
instructions, 1μg of the extracted RNA was reverse-transcribed into cDNA using 
Stratascript cDNA synthesis kit (Stratagene). Oligo-dT primers were used in the assay to 
selectively amplify cellular mRNAs. Gene-specific, intron-spanning primers and probes 
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used in these assays are listed below (Table 2.1). TaqMan® Fast Universal PCR master 
mix (Applied Biosystems) was added in 10μl of reaction mixtures in a 96 well plate and 
the fast amplification cycle (20 sec at 95°C, followed by 40 cycles of 3 sec at 95°C and 30 
sec at 60°C) of an ABI Prism 7500 fast real-time PCR system was used to perform the 
experiments. Initially several house-keeping genes (RPLPO, ß-GUS, GAPDH, ß-2-
microglobulin, phosphoglycerate kinas 1 and ß-actin) were tested and the expression 
level of RPLPO was found to be the most stable during influenza virus infection of 
monocytes. Therefore, RPLPO was applied to normalize the data. The relative 
expression levels of different genes were determined (2-∆∆CT) by using the method of 
Livak and Schmittgen (177). 
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Table 2.1: Primers and probes for two-step RT-PCR assay. 
 
Target 
gene 
Sequences (5’-3’) References 
 
RPLPO 
Fwd: CTGATTACACCTTCCCACTTGCT 
Rev: AGCCACAAATGCAGATGGATCA 
Probe: FAM-AAGGCCTTGACCTTTTC-NFQ 
 
 
CD11c 
Fwd: CTGATTTCCTGACCCACCTTCA 
Rev: ACCTCAGGCAGTCAGCAATG 
Probe: FAM-CTGTGCTGGACTGCTC-NFQ 
 
 
CCR5 
Fwd: GCAGAGCAGCTGAGACATCT 
Rev: GGACTTGTCGTCTGATAATCCATCT 
Probe: FAM-CAACCCAGGAGGCCTT-NFQ 
 
(176) 
 
CCR7 
Fwd: GTGGTGGCTCTCCTTGTCA 
Rev: AATCGTCCGTGACCTCATCTTG 
Probe: FAM-CAGGCACACCTGGAAAA-NFQ 
 
(176) 
 
IL-10 
Fwd: AGGACCAGCTGGACAACATG 
Rev: GGTAAAACTGGATCATCTCCGACAA 
Probe: FAM-CCAGGTAACCCTTAAAGTC-NFQ 
 
(176) 
 
IL-12 
Fwd: CTACACCAGCGGCTTCTTCAT 
Rev: GCTTCAGCTGCAGGTTCTTG 
Probe: FAM-CAGGGACATCATCAAACC-NFQ 
 
(178) 
 
TGF-ß 
Fwd: CCCTGCCCCTACATTTGGA 
Rev: TGTACAGGGCCAGGACCTT 
Probe: FAM-CCTGGACACGCAGTACAG-NFQ 
 
(176) 
 
IFN-α 
Fwd: GCTGCTCTCTGGGATGTGA 
Rev: TTTGTCCCAGGAGCATCAAGAC 
Probe: FAM-CCTGCCTCACACCCATAG-NFQ 
 
(178) 
 
TNF-α 
Fwd: TTACCGAATGCCTTCCAGTCAAT 
Rev: GGGCTACAGGCTTGTCACTT 
Probe: FAM-CCAGACACTCAGATCAT-NFQ 
 
(178) 
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Alpha-naphthyl acetate esterase (ANAE) assay 
 Mock or virus infected cells were collected at 4 days p.i., washed twice with PBS 
and then smeared onto an 8-well slide. The slide was air-dried, fixed and then analyzed 
for ANAE activity using alpha-naphthyl acetate (Sigma Aldrich) as the substrate as per 
the manufacturer’s instructions and in accordance of previously published methods 
(179). Presence of ANAE was determined microscopically by the appearance of dark, 
black granulations at the site of enzymatic activity. 
 
DQ-ovalbumin (DQ-OVA) endocytosis assay 
 DQ-ovalbumin (DQ-OVA, Molecular Probes) is a pH insensitive BODIPY-
conjugated self-quenching dye which emanates fluorescence (505-515nm) upon 
protease degradation following endocytosis. On day 4 p.i., cells were collected, washed 
twice in PBS and then resuspended at 5 x 105 per ml in cRPMI medium. DQ-OVA (10μl, 
1mg/ml) was added to 100μl of cell suspensions and incubated at 37°C or 4°C (negative 
control). After 1 hr of incubation, cells were washed thrice with ice-cold cRPMI media 
containing 10% autologous horse serum to remove unbound or non-specifically bound 
antigens. Cell samples were then resuspended in FACS buffer and evaluated by flow 
cytometry. The endocytic capacity of mock or virus infected cells was determined by the 
differences in mean fluorescence intensities between the treated and control samples. 
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Statistical analysis 
 Data were analyzed by the one-way analysis of variance (ANOVA) and the 
Tukey’s multiple comparison tests using the GraphPad Prism 5 statistical software 
(GraphPad Software Inc.). A p value of less than 0.05 (95% confidence level) was 
considered to be significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Saikat Boliar 2009 
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CHAPTER III 
RESULTS 
 
 
The hypothesis of whether influenza virus infection hinders monocyte 
differentiation into DC was tested by evaluating the following results. In specific aim 1, 
transcription of viral genomic RNA and subsequent viral protein synthesis and progeny 
virus production in infected monocytes was quantified to assess whether equine 
influenza virus can replicate in equine monocytes cultured with both GM-CSF and IL-4. 
The ability to induce apoptosis in infected cells indicated viral cytotoxicity. In specific 
aim 2, microscopical examination for morphologies and analysis by flow cytometry for 
phenotypic expression of DC surface markers was done to evaluate the ability of 
influenza virus infected monocytes to differentiate into DCs. Functional inhibition due to 
the viral infection was measured by the endocytic ability and cytokine production by 
infected monocytes. Finally, an H3N8 virus (KY/02) and another NS1-truncated virus was 
used in specific aim 3 to evaluate if the viral inhibition is dependent on virus subtype 
and the NS1 protein function.   
 
 
 
 
 
Proportion of monocytes in adherent cell population
 Following isolation of PBMC, 
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Influenza viral RNA transcription in monocytes cultured with GM-CSF and IL-4 
 The ability of equine influenza virus (NY/73, H7N7 subtype) to replicate in 
actively differentiating monocytes was first evaluated by examining viral genome 
transcription. Before infecting with the virus, monocytes were pre-incubated overnight 
with GM-CSF and IL-4 to initiate the differentiation process. Upon entering into cells, 
viral genome transcription was evaluated by quantifying influenza virus nucleoprotein 
(NP) RNA levels at various time points post-infection (0, 4, 8, 12 and 24 hr p.i.). 
Monocytes in culture for DC differentiation allowed initiation of influenza genome 
transcription as viral NP RNA level continued to increase until 12 hr p.i. when it reached 
about 12-fold the amount of initial infectious viral RNA (Figure 3.3). However, after 12 
hr p.i., viral RNA level started to decline. On the other hand, in UV-inactivated influenza 
infected cells, no significant increase in NP RNA level was observed which further 
confirmed successful inactivation of the virus through UV irradiation. However, 
detection of NP RNAs in UV-inactivated influenza infected cells showed that those 
viruses retained their cellular attachment and entry capabilities.    
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Figure 3.3: Viral genome transcription in influenza infected monocytes. Nucleoprotein 
(NP) RNA levels in UV-inactivated and live virus (NY/73) infected monocytes were 
measured by RT-PCR assays and were normalized based on RPLPO RNA levels. Results 
are expressed as fold-increase (mean ± SD) over 0 hr p.i.  
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Influenza viral protein synthesis in monocytes cultured with GM-CSF and IL-4 
 Since equine influenza virus (NY/73, H7N7) was able to transcribe its RNA 
genome in infected monocytes, we next evaluated whether it could translate its viral 
proteins. When virus infected monocytes were analyzed by flow cytometry for NP 
protein levels, an early restriction in viral protein synthesis was observed (Figure 3.4). 
Following infection, the virus started to synthesize viral NP protein which was evident by 
the sharp increase in mean fluorescence intensity (MFI) at 4 hr p.i. However, after this 
time point, NP protein level decreased continuously. At 24 hr p.i., fluorescence for NP 
protein was almost half that of at 4 hr p.i. This showed that monocytes stimulated for 
DC differentiation imposed an early inhibition in viral protein synthesis. 
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Progeny virus production in monocytes cultured with GM-CSF and IL-4 
 Ability of GM-CSF and IL-4 pre-treated monocytes to support influenza virus 
replication was further evaluated by quantification of progeny virus production by 
infected cells. Cell supernatants were collected from infected monocytes (2 X106 cells, 
MOI of 5 EID50 units per cell) at 0 and 24 hr p.i. and presence of live virus particles was 
measured by 50% egg infectious dose assay. Loose attachment of monocytes to the 
plate prevented vigorous washing of cell surface after infection which resulted in 
substantial titer at 0 hr p.i. However, when viral titer at 24 hr p.i. was compared to that 
of 0 hr, only 10-fold increase in EID50 titer was observed (Table 3.1). This is significantly 
less than what is normally observed with more permissible cells such as MDCK (2 X 106 
cells, MOI of 5 EID50 units per cell; Table 3.1). This demonstrated that GM-CSF and IL-4 
treated monocytes were non-permissive to influenza virus as only limited progeny virus 
production was achieved. 
 
Table 3.1: EID50 titers of influenza virus infected monocytes and MDCK cells. 
EID50 titer 0 hr p.i. 24 hr p.i. Fold difference 
Monocytes      
(GM-CSF & IL-4) 
9.8 X 104 10.5 X 105 10.7 
MDCK cells 2.81 X 105 6.58 X 107 234.1 
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Level of apoptosis of developing DCs following influenza infection 
 Having established that influenza virus infection of differentiating monocytes is 
abortive or minimally-productive, we next investigated whether this limited virus 
replication could inflict any toxic effect i.e. apoptosis in differentiating monocytes. 
Mock- or virus-infected monocytes were cultured for 4 days in cRPMI supplemented 
with GM-CSF and IL-4. Annexin-V (apoptosis) and propidium iodide (loss of cell 
membrane integrity) staining of cells revealed that the presence of GM-CSF and IL-4 in 
the culture media of mock-infected monocytes did not adversely affect their viability 
(86.7% vs 84.0%, data not shown). When influenza virus-infected monocytes were 
cultured with GM-CSF and IL-4 for 4 days, the level of apoptosis was significantly higher 
than in mock infected cells (10.3% vs. 1.8%, p <0.01, Figure 3.5). However, considering 
the fact that an infectious dose of 5 EID50 units per cell succeeded at inducing apoptosis 
in only about 10.3% of the cells and the majority of cells (about 76.9%) were still viable 
based on trypan blue staining at 4 days p.i., it can be concluded that influenza virus 
infection did not induce substantial toxicity or apoptosis in developing DCs. 
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Morphology of mock and influenza virus (NY/73) infected monocytes 
 The morphological distinction between mock- or influenza-infected monocytes 
was determined by inverted light microscopy (Figure 3.6). After 4 days of incubation, 
mock-infected monocytes showed typical DC-like appearances such as finger-like 
projections. Fully differentiated DCs were observed as loose floating clumps of large, 
viable cells. On the other hand, infected cells failed to acquire DC-like processes and 
many cells were found to float as a single cell or dense clumps of dark cells. Monocytes 
infected with UV inactivated virus exhibited DC morphology, although the proportion of 
DC-like cells was smaller than in the mock infected population (Figure 3.6). The average 
diameter, as obtained by Vi-Cell TM cell viability counter (Beckman Coulter), also 
indicated that influenza-infected monocytes did not increase significantly in size as 
compared to their mock-infected counterparts (Figure 3.7). Differences between live 
influenza infected monocytes and both mock and UV-inactivated virus infected cells 
were also significant (Figure 3.7). Analysis by flow cytometry, as well, revealed a lower 
degree of granularity for the virus-infected cell populations as most of the virus infected 
cells, similar to monocytes, were still congregated in the lower right quadrant of the dot 
plot. 
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Figure 3.6: Light microscopy images (10X and 100X magnifications). Mock, UV-
inactivated and live influenza virus (NY/73) infected monocytes were cultured in cRPMI 
media supplemented with GM-CSF and IL-4 for 4 days and observed for DC morphology 
under a light microscope. 
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Expression of DC surface molecules on influenza virus (NY/73) infected monocytes 
 Successful differentiation of monocytes into DCs was confirmed by analysis of a 
set of distinctive surface molecules. Monocytes were infected with 5 EID50 units per cell 
of live influenza virus or equivalent amount of UV-inactivated virus; cultured in presence 
of GM-CSF, IL-4 for 4 days and then compared with their mock-infected counterparts for 
relevant phenotypes. Differentiated DCs are characterized by high levels of CD11c, 
CD1b, CD86, MHC I and MHC II. Accordingly, mock-infected monocytes which effectively 
differentiated into DCs, up-regulated CD11c gene expression by almost 20-fold (p <0.05) 
compared to non-stimulated monocytes (Figure 3.8). In contrast, CD11c expression on 
live influenza infected monocytes was nearly negligible (p<0.05 vs mock) and UV-
inactivated virus treated monocytes exhibited only moderately (5-fold) increased CD11c 
gene expression (Figure 3.8). Similarly, CD172a (a myeloid marker) was found on 86% of 
mock–infected monocytes whereas only 66.1% and 36.2% of UV-inactivated or live virus 
treated cells were positive for this marker respectively (Figure 3.9). This expression level 
of CD172a on live virus infected monocytes was significantly lower (p <0.05) than the 
mock cell population. Mock-infected cells also had a significantly higher (p <0.05) 
number of CD1w2 (human CD1b homolog) positive cells than either of the virus infected 
cell populations (Figure 3.10). Influenza virus infected monocytes also failed to up-
regulate expression of “immature” DC-associated chemokine receptor, CCR5 as 
efficiently as mock or UV-inactive virus treated cells (Figure 3.8). On the other hand, 
expression of CCR7, which is predominantly found at high levels on “mature” DCs, did 
not vary significantly among mock and virus treated cell populations (Figure 3.8). 
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However, percentage of cells expressing CD86, MHC I and MHC II were comparable 
among mock, UV-inactivated or live influenza virus infected cells (Figure 3.11). On the 
other hand, when the mean fluorescence intensities (MFI) were evaluated, these were 
considerably higher for both UV-inactivated and live virus infected cells as compared to 
mock samples (Figure 3.12). These results indicated that influenza virus infection of 
monocytes impeded expression of different surface antigens characteristic of DC 
differentiation. Since the phenotype of UV-inactivated virus treated monocytes, as 
evaluated from the surface antigen expression profile, lay intermediate between mock- 
and live influenza virus infected cells, it appears that at least limited viral replication was 
necessary for significant inhibition of monocyte differentiation into DCs. 
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Figure 3.8: Gene expression of CD11c, CCR5 and CCR7. Relative RT-PCR was used to 
measure gene expression levels. Data were normalized based on house-keeping gene, 
RPLPO and shown as mean ± SD. A p value of 0.05 or less was considered significant.  
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Figure 3.9: Surface expression of 
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Figure 3.12: Mean fluorescence intensity (MFI) of CD86, MHC I and MHC II surface 
expressions. Data are shown as mean ± SD (N=4). A p value of less than 0.05 was 
considered significant. 
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Alpha-naphthyl acetate esterase (ANAE) activity of influenza virus (NY/73) infected 
monocytes 
 Dendritic cell differentiation from monocytes was further investigated by 
cytochemical staining for ANAE. This is a family of non-specific esterase enzymes which 
is found uniformly throughout the cytoplasm of monocytes and macrophages (180, 
181). Mock infected monocytes which successfully differentiated into DCs, had very 
faint and focal ANAE staining mainly around the nucleus (Figure 3.13). Influenza virus 
infected cells retained considerable enzymatic activity as observed by the dense and 
diffuse ANAE staining throughout the cytoplasm. The staining for UV inactivated virus 
treated cells fell intermediate between mock- and live virus infected cells. 
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Figure 3.13: ANAE activity in influenza infected monocytes. Mock, UV-inactivated and 
live influenza virus (NY/73) infected monocytes were cultured in presence of GM-CSF 
and IL-4 for 4 days and then stained for non-specific esterase. Dark black granulations 
are indicative of ANEA activity. 
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Endocytosis by influenza virus (NY/73) infected monocytes 
 The ability of influenza infected monocytes to acquire DC-like functions was 
evaluated by determining their antigen endocytosis capability. Mean fluorescence 
intensity of DQ-ovalbumin which liberates fluorescence upon endocytosis was used as 
an indication of antigen uptake ability. As shown in Figure 3.14, mock infected cells had 
significantly higher (p<0.05) endocytic function (high MFI), while live virus infected ones 
failed (low MFI) to uptake DQ-OVA through receptor mediated endocytosis. Consistent 
with other results, UV-inactivated virus treated monocytes showed a partially reduced 
endocytic activity compared to mock cells although significantly more than live influenza 
infected monocytes. These data suggest that live influenza virus infection successfully 
prevented monocytes from acquiring endocytic function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mock 
 
Figure 3.14: Receptor-mediated endocytosis of DQ
and live influenza virus (NY/73, H7N7) infected 
with DQ-ovalbumin for 1 h at 4°C (black line) or 37°C (green). Level of antigen 
endocytosis was analyzed
intensity (MFI). Numbers in the figures indicate averag
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Cytokine production by influenza virus (NY/73) infected monocytes 
 Since cytokines play a critical role in monocyte differentiation into DCs, 
production of IL-10, IL-12 and TGF-ß which are known to influence DC development was 
analyzed. Mock or influenza virus infected cells were analyzed for their intracellular 
cytokine mRNA synthesis. Mock infected cells had considerably higher IL-12 mRNA level 
than live influenza virus infected monocytes (Figure 3.15). On the other hand, virus 
infection enhanced IL-10 mRNA transcription by 3-fold over mock infected cells (Figure 
3.15). Another cytokine, TGF-ß which favors DC differentiation was also significantly 
down-regulated in influenza virus infected monocytes (Figure 3.15, p <0.05). These data 
indicated that IL-12, a pro-inflammatory cytokine produced by DCs, was down-regulated 
in influenza virus infected monocytes whereas IL-10, a reciprocal regulatory cytokine to 
IL-12, was up-regulated which would be favorable for arresting monocyte differentiation 
into DCs.  
 Other inflammatory cytokines, however, were differently influenced by the viral 
infection. Live influenza virus infection significantly up-regulated gene expression of IFN-
α and TNF-α as compared to mock infected monocytes (Figure 3.15, p <0.05). 
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Figure 3.15: Cytokine production by influenza infected monocytes. Mock, UV-
inactivated or live influenza virus (NY/73) infected cells were cultured in GM-CSF and IL-
4 for 4 days and mRNA levels of IL-10, IL-12, TGF-ß, IFN-α and TNF-α were quantified by 
real-time PCR. RPLPO mRNA levels were used to normalize the data. Results are shown 
as mean ± SD. A p value of less than 0.05 was considered significant. 
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Expression of DC surface molecules on monocytes infected with KY/02 and a NS1-
defective influenza virus 
 An H3N8 equine influenza virus (KY/02) and its NS1-truncated variant (KY/02 
NS1-73) were utilized in order to investigate whether the viral inhibition is subtype-
dependent and if viral NS1 protein plays any role in the process. Similar to the 
experiments with NY/73 virus, expression of DC markers such as CD11c and CD172a was 
measured. The mock infected cells, as expected, enhanced their expression of CD11c 
significantly (p <0.05) with respect to monocytes. But its expression on both wild type 
and NS1-truncated virus infected monocytes was either comparable to or less than 
monocytes and significantly lower than mock infected cells (Figure 3.16, p<0.05). 
Similarly, fewer wild type virus (KY/02) infected monocytes expressed CD172a on their 
surface than mock infected cells. The expression of this myeloid marker was even lower 
in NS1-truncated virus infected monocytes (Figure 3.16). This demonstrated that both 
H3N8 wild type and NS1-defective influenza viruses were able to hinder monocytes 
from attaining distinctive DC phenotypes.    
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Figure 3.16: Expression of DC surface on H3N8 influenza infected monocytes. Relative 
RT-PCR was used to measure gene expression levels of CD11c. Expression levels were 
normalized based on house-keeping gene, RPLPO. Surface expression of CD172a was 
measured by flow cytometry. Data are shown as mean ± SD. A p value of 0.05 or less 
was considered significant. 
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Endocytosis by monocytes infected with KY/02 and a NS1-defective influenza virus 
 DCs are the most potent APCs and efficient endocytosis is a prerequisite for 
presenting antigens on MHC molecules. When KY/02 wild type and the NS1-truncated 
influenza virus infected monocytes were examined for their ability to uptake ovalbumin, 
both wild type and NS1-truncated virus infected cells showed considerably less 
endocytic function compared to mock infected monocytes (Figure 3.17). This indicated 
that H3N8 influenza virus, similar to H7N7 subtype, was also able to inhibit antigen 
uptake by monocytes and truncation of its NS1 viral protein did not hamper this 
inhibition by the virus.  
 
 
Figure 3.17: Endocytosis of DQ-ovalbumin by H3N8 influenza infected monocytes. 
Mock, KY/02 and NS1-truncated influenza virus (H3N8) infected monocytes at 4 days p.i. 
were incubated with DQ-ovalbumin for 1 h at 4°C (black line) or 37°C (green). Level of 
antigen endocytosis was analyzed by flow cytometry and measured by the mean 
fluorescence intensity (MFI). Results are presented as mean ± SD. 
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Cytokine production by monocytes infected with KY/02 and a NS1-defective influenza 
virus 
 As described in chapter I (section 2.2.8), NS1 protein of influenza virus is a strong 
antagonist of cellular interferon production. To evaluate whether truncation of NS1 
protein affected this function, IFN-α productions by mock, wild type and NS1-defective 
influenza virus infected monocytes were compared. Not surprisingly, NS1-truncated 
influenza virus allowed infected monocytes to produce significantly more IFN-α (Figure 
3.18).   
 
 
Figure 3.18: IFN-alpha production by H3N8 influenza infected monocytes. Relative RT-
PCR was used to measure gene expression levels. Data were normalized based on 
house-keeping gene, RPLPO and shown as mean ± SD. A p value of 0.05 or less was 
considered significant. 
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CHAPTER IV 
DISCUSSION 
 
 
 In spite of the extensive research done on influenza virus, our understanding of 
the mechanism of its pathogenesis at the cellular level still remains incomplete. Because 
of the segmented genome, it can undergo gene reassortment or antigenic shift which 
can be indicted for the three documented human pandemics in the last century (5). 
Again, its negative sense RNA genome requires viral RNA dependent RNA polymerase 
for its replication whose error prone properties enable the virus to introduce point 
mutations or antigenic drift which helps the virus in evading existing host antibodies. 
While these strategies counteract the humoral immune response, influenza virus has 
also evolved to escape the cell mediated immunity as well. For example, influenza virus 
NS1 protein inhibits T cell activation and IFN-γ production (64). However, only limited 
information is available on influenza virus mediated inhibition of the innate immunity. 
DCs play a vital role in innate immunity as well as activation of adaptive immunity and as 
mentioned in Chapter I, monocytes are a major source of these APCs, particularly during 
infections. Therefore, in this dissertation, the effects of influenza virus infection on 
monocyte differentiation into DCs were studied. 
 An equine virus-host model system has been utilized to evaluate the hypothesis. 
Since influenza virus infections of mice do not always simulate natural infections, the 
ability to examine the effects of equine influenza viruses on equine monocytes provides 
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a distinctive opportunity of studying a virus in its natural host. The availability of large 
amounts of blood from horses also satisfies the needs of the experiments, which could 
otherwise pose a difficulty in human or mouse model systems. The discrete features of 
two equine influenza subtypes (H7N7 and H3N8) also offered a prospect of investigating 
whether viral subtype differences play any role in the process. It is noteworthy to 
mention that equine-1 (H7N7) influenza viruses possess the basic amino acid containing 
highly cleavable HA proteins which is a phenotypic attribute of pathogenic avian 
influenza viruses. However, despite being highly virulent in mice, it only causes a mild 
disease in horses (81). This offers the unique chance to investigate the effects of a 
genotypically predicted highly virulent mammalian influenza virus on the differentiation 
of monocytes into dendritic cells. A NS1-defective equine influenza virus was also 
tested. As described in chapter I (section 2.2.8.), NS1 protein of influenza virus plays an 
important role in viral pathogenesis and immune-evasion. The NS1-truncated virus that 
was used in the experiments lacks the C-terminal “effector domain” which mediates 
several of its anti-immune activities (section 2.2.8). So, contrasting the effects of wild-
type and NS1-defective viruses on DC differentiation could illuminate additional roles of 
this viral protein (NS1) in influenza virus pathogenesis. 
 During influenza virus infection, respiratory epithelial cells secrete an array of 
inflammatory cytokines and chemokines that lead to a massive influx of immune cells 
including monocytes into the airway mucosa. Microbial infections and allergens are 
known to stimulate increased GM-CSF production by airway epithelial cells (182, 183), 
that along with other cytokines can drive the priori uncommitted monocytes, now in the 
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inflammatory milieu, to differentiate into either macrophages or DCs in order to supply 
adequate APCs at the site of infection. Pre-treatment of cells with cytokines such as GM-
CSF have been found to modulate the outcome of viral infections. GM-CSF is a potent 
cytokine which can stimulate cellular metabolism, RNA transcription and protein 
synthesis as well as endocytosis (184). Accordingly, it has been shown that influenza 
progeny virus production and cytotoxicity is increased when monocytes are cultured 
with GM-CSF alone leading them towards the macrophage lineage (185). Similar results 
are obtained when GM-CSF treated mononuclear phagocytes are infected with HIV (186, 
187). IL-4, a Th2 type cytokine, also enhances replication of SIV when given to macaque 
monkeys (188). Although the effects of GM-CSF and IL-4 on virus replication have been 
demonstrated separately, the fate of virus infected monocytes cultured with both GM-
CSF and IL-4 and thus differentiating towards DCs, was yet unknown.  
 While monocytes in the blood stream are highly unlikely to become infected 
with influenza virus, monocytes in the respiratory mucosa would come in contact with 
an enormous number of virus particles produced by infected airway epithelial cells. So 
in specific aim 1, the replication behavior of equine influenza virus in monocytes 
cultured in the presence of both GM-CSF and IL-4 was characterized. Adherent cells 
were used as the source of monocytes since about 73.6% of the population was 
consisted of CD14 positive cells (Figure 3.1). An infectious dose of 5 EID50 units per cell 
was chosen to ensure viral exposure to most of the cells. It was found that equine 
influenza virus successfully infected monocytes, as about 59% of the adherent cells 
expressed viral NP protein at 24 hr p.i. when analyzed by flow cytometry (Figure 3.2). 
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Since It is known from a published report that influenza virus can not readily infect 
lymphocytes, the reason for the other 41% of the cells not expressing viral NP protein 
could be traced to the fact that about 73.6% of the adherent cell population was 
monocytes (CD14 positive, Figure 3.1), while the rest would be comprised of primarily 
lymphocytes, which are non-permissive to influenza infection (189). Successful 
replication of the virus was also evaluated by its genome transcription ability, viral 
protein synthesis and progeny virus production. As shown in Figure 3.3, the live virus 
could transcribe its viral genome as opposed to the UV-inactivated virus. However, viral 
protein synthesis ceased very early at 4 hr p.i. This resulted in a very limited progeny 
virus production. The lack of cytotoxicity (Figure 3.5) of virus infected monocytes could 
be associated with the inefficient viral protein synthesis. This is in stark contrast to the 
infection of only GM-CSF pre-treated monocytes where influenza virus replicates 
productively and induces much higher rate of apoptosis (185). Similar results are also 
observed when equine monocytes are infected with equine influenza viruses (personal 
communication, Liang Zhang). The reason for this inhibition due to GM-CSF and IL-4 pre-
treatment of monocytes is yet unclear. The most plausible explanation is that GM-CSF 
and IL-4 pre-treatment sets off monocyte differentiation towards DCs and stimulates 
production of cytokines (TNF-α, IFNs) which in turn can block influenza virus replication. 
In fact, GM-CSF and IL-4 pre-treated monocytes, when infected with influenza virus, 
expressed significantly higher levels of IFN-α and TNF-α than their mock infected 
counterparts (Figure 3.15). Several reports have shown that IFNs induce expression of 
anti-viral genes such as Mx and viperin which can inhibit influenza virus replication (145, 
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190). While Mx inhibits viral mRNA synthesis, viperin interferes with the fluidity of 
cellular lipid rafts and thereby prevents budding of progeny viruses from infected cells. 
TNF-α also possesses a strong anti-influenza activity (191). Pre-treatment of otherwise 
susceptible cells such as MDCK with TNF-α makes them resistant to viral cytopathic 
effects by inhibiting viral protein synthesis. Additionally, the reduced level of apoptosis 
in GM-CSF and IL-4 pre-treated monocytes could be due to the anti-apoptotic effects of 
IL-4. It can activate signal transducer and activator of transcription 6 (Stat-6) and 
phosphatidylinositol 3 kinase (PI3K) pathways which up-regulate anti-apoptotic protein 
Bcl-xL and thereby prevent cells from undergoing apoptosis (192, 193). So these results 
identify that influenza virus infection of blood monocytes culminate into two distinct 
outcomes depending upon whether those cells are differentiating towards macrophages 
or DCs. 
 Although influenza virus undergoes restricted replication in differentiating 
monocytes, it was further investigated if the viral infection had any morphological or 
functional effects on monocyte differentiation into DCs. When monocytes differentiate 
into DCs, they acquire a distinctive DC-like morphology with veils and large finger-like 
projections. In these experiments, mock and UV-inactivated virus infected monocytes 
acquired the DC-like morphology, but live influenza virus infected monocytes remained 
round and lacked dendritic processes (Figure 3.6). When cell diameter was measured, 
equine monocytes had an average diameter of 8.92μm. Mock and UV-inactivated virus 
infected monocytes, which successfully differentiated into DCs, had significantly 
increased their average diameter to 10.00μm and 9.88μm, respectively. On the 
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contrary, live virus infected monocytes failed to increase in size as their average 
diameter (9.03μm) remained close to that of monocytes (Figure 3.7). Live virus infected 
monocytes were also unsuccessful in increasing their cellular granularity as fewer cells 
moved to the upper right quadrant of the dot plot compared to both mock and UV-
inactivated virus infected monocytes (Figure 3.7). Although the precise reason for the 
inability of influenza infected monocytes to attain DC-morphology is unclear, viral 
attachment and entry alone was not adequate to bring about the changes. Viral 
genomic RNA transcription and limited viral protein synthesis was required for the 
inhibition because UV-inactivated influenza infected monocytes successfully acquired 
the DC-like morphology. These results showed that live influenza virus infected 
monocytes failed to attain the morphological characteristics of DCs. 
 Apart from the morphological alterations, influenza virus infection of monocytes 
also modified expression of different DC surface molecules. CD11c, an integrin, is a 
specific marker for DCs and is expressed abundantly on myeloid and other types of DCs 
(194). Thus, mock infected cells up-regulated expression of CD11c significantly (20-fold, 
p< 0.05) over untreated monocytes (Figure 3.8). On the contrary, CD11c expression on 
live virus infected monocytes was almost negligible. Similarly, live virus infected 
monocytes failed to up-regulate expression of several other DC markers (CD172a, 
CD1w2, CCR5; Figure 3.8 and 3.9). Interestingly, surface markers on monocytes infected 
with UV-inactivated influenza virus, although considerably higher than live influenza 
virus infected cells, were moderately lower than mock infected monocytes. The 
expression of CD1w2 (human CD1b homolog), in particular, was remarkably low (Figure 
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3.9). However, this finding corroborates with a previous report that TLR7/8 agonists 
have an inhibitory effect on the surface expression of CD1 family members (195). 
Although UV-inactivated influenza viruses could not replicate their viral genome, they 
would retain enough genomic RNA to stimulate TLR7/8 in monocytes (Figure 3.3). 
Considerably enhanced expression (MFI) of CD86, MHC I and MHC II on both UV-
inactivated and live influenza virus infected monocytes was also observed, which 
suggests an involvement of TLRs which when activated are known to stimulate 
expression of these co-stimulatory molecules (196). As suggested above, UV-inactivated 
influenza virus, possibly through activation of PAMPs such as TLRs, was able to partially 
modulate the phenotypic characteristics, but complete inhibition of appearance of DC-
specific markers required at least limited viral replication as exemplified by live influenza 
infected monocytes. 
 Effects of influenza virus infection on monocyte differentiation were further 
characterized by cytochemical staining for ANAE. Splenic and tonsilar DCs are negative 
for ANAE, but monocyte derived DCs retain a little enzymatic activity, although the 
staining appears to be much more focal (197, 198). Accordingly, mock infected 
monocytes which successfully differentiated into DCs had retained very little enzymatic 
activity as compared to the substantial staining in live influenza infected monocytes. UV-
inactivated virus infected monocytes, again, showed an intermediate phenotype (Figure 
3.13). These results further demonstrated that live influenza virus infected monocytes 
failed to attain cytochemical characteristics of fully differentiated DCs. 
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 An important finding was the ability of influenza virus to affect the antigen-
capturing capability, the hallmark function of any APC including DCs. Antigen 
endocytosis by live influenza infected monocytes were significantly reduced compared 
to mock infected cells (Figure 3.14, p <0.05). UV-inactivated virus infected monocytes 
showed similar endocytic capability to that of mock samples suggesting that functional 
inhibition of monocyte-derived DCs required active viral replication. This effect of 
influenza mediated inhibition of endocytosis is far-reaching since this would in turn 
prevent infected monocyte derived DCs from presenting the viral antigen to T cells and 
thereby blocking any subsequent activation of adaptive immune response.  
 Next, the mRNA expression of cytokines that are known to influence monocyte 
differentiation into dendritic cell was studied. IL-10 which is an anti-inflammatory and 
immunosuppressive cytokine which was synthesized at increased levels both in UV-
inactivated and live influenza infected cells compared to mock infected monocytes 
(Figure 3.15). On the contrary, production of IL-12, an inflammatory cytokine, was 
higher in mock samples than in live influenza infected monocytes. TGF-ß also followed a 
similar pattern as of IL-12. Now, it is known that IL-10 inhibits development of DCs from 
monocytes while IL-12 and TGF-ß favors the differentiation process (168, 199). 
Additionally, differentiated DCs produce large amounts of IL-12 that in turn drive CD4+ T 
cells towards a Th1 type immune response which is necessary for clearance of influenza 
virus infection (200, 201). On the other hand, IL-10 has a detrimental effect on the host 
immune response and subsequent recovery from influenza infection (202). It also 
increases susceptibility to secondary bacterial infections (203). These results showed 
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that influenza virus infection of monocytes resulted in production of a coordinated 
cytokine profile that not only inhibited DC differentiation but also prevented 
development of a Th1 type immune response and recovery from virus infection. 
 These conclusions were further extended to include the other subtype (H3N8) of 
equine influenza virus and to address the possibility of a virus subtype specific 
inhibition. Since influenza virus NS1 protein has an established immune antagonistic 
activity and is also known to inhibit maturation of DCs (section 2.2.8, chapter I), an NS1-
truncated virus was used to evaluate the role of this viral protein in this inhibition 
process. As evidenced in Figure 3.16, both the wild type virus (KY/02) and its NS1-
defective variant inhibited phenotypic expression of DC surface markers. Both viruses 
were also able to block antigen endocytosis by infected monocytes (Figure 3.17). Since 
the NS1-truncated virus (NS 1 -73 a.a.), although lacks the effector domain but retains 
the RNA-binding domain (section 2.2.8), it is possible that only the RNA-binding domain 
was sufficient for the viral inhibition of DC differentiation. However, it is particularly 
important to note that the inhibition by NS1-defective variant was more enhanced than 
the wild type virus (Figure 3.16). This data not only proved that completely functional 
NS1 protein was not necessary for influenza virus mediated inhibition of monocyte 
differentiation, but also indicated to a possible mechanism of this viral inhibition. IFN-
α/ß, when added to the culture media, have been shown to exhibit a negative 
regulatory effect on differentiation of fully functional DCs from monocytes (204). In 
these experiments also, NS1-truncated influenza virus infected monocytes synthesized 
more IFN-α mRNA than the wild type virus (Figure 3.18). Although no direct co-relation 
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could be established here, IFN-α produced by infected monocytes can act in an 
autocrine negative-feedback mechanism to inhibit their development into DCs. 
Nonetheless, these results demonstrated that the viral inhibition of monocyte 
differentiation is not specific for the H7N7 subtype as H3N8 subtype was also able to 
block DC development. It further showed that influenza virus can inhibit monocyte 
differentiation into DC independent of complete NS1 protein activity.   
 Although the heterogeneity of monocyte-derived DCs makes their precise 
characterization very intricate, experiments in this dissertation provided a general 
insight into the effects of influenza virus infection of monocytes that are cultured in 
vitro for differentiation into DCs. These experiments, taken together, demonstrated that 
equine influenza virus could successfully infect and transcribe its genomic RNA in GM-
CSF and IL-4 pre-treated monocytes, although an early inhibition of viral protein 
synthesis prevented efficient progeny virus production. It also showed that infection 
with influenza virus prevented monocytes from differentiating into DCs. Although UV-
inactivated virus imposed a partial inhibition, complete morphological and functional 
inhibition required at least limited viral replication. The mechanism of this inhibition, 
although unconfirmed in this dissertation, possibly involves TLR-mediated activation of 
cytokine (e.g. IFNs) productions. Since DCs are critical in initiating immune responses 
against viral infections, this inhibitory effect of influenza virus would block an early 
development of virus specific immune activation. For an acute infection like influenza, 
this will provide ample opportunities to the virus for efficient replication and 
transmission to other susceptible hosts. So, the experiments described in this 
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dissertation identify a new strategy by influenza virus to stall activation of an innate and 
subsequent adaptive immune response and thereby evade an anti-viral immunity.   
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Future research prospect 
 Findings of this dissertation research have shown that influenza virus infection of 
blood monocytes can inhibit their differentiation into DCs and have alluded to possible 
mechanism of this inhibition. However, the precise mode of this viral inhibition remains 
to be ascertained. It needs to be determined whether activation of TLR pathways plays 
any role in this process and if it does, which TLR in particular is resdponsible. 
Additionally, although it has been shown in this dissertation that activity of fully 
functional NS1 protein is not necessary for the viral inhibition, roles of other viral 
proteins such as HA and NA are yet to be defined. This offers an interesting avenue of 
future research.  
Since at least a proportion of DCs develop from blood monocytes and influenza 
virus infection of monocytes inhibited their development into DCs; this would impair 
proper immune activation and thereby exacerbate the disease condition or delay 
recovery. Revelation of the molecular mechanism of this inhibition would be important 
because that knowledge can be further employed for improvement of vaccines. 
Prospects of different vaccine adjuvant which may help monocytes overcome virus 
mediated inhibition of DC differentiation could be investigated. 
The results described in this dissertation may also serve as the basis for further 
research to better understand influenza virus replication as well as improvements of 
vaccines. Since only GM-CSF pre-treated monocytes are known to be permissive for 
influenza infection and the experiments here showed that GM-CSF and IL-4 pre-
treatment inhibited viral replication, particularly at the stage of viral protein synthesis; 
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advanced research could be carried out to elucidate the precise molecular mechanism 
of this inhibition. Development of monocytes towards DCs may stimulate gene 
transcription and expression of cellular proteins (that may not be activated in 
macrophages) which may block viral protein synthesis. Such discoveries may lead to 
development of novel anti-viral drugs. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Saikat Boliar 2009 
92 
 
References 
 
1. Shope, R.E. 1931. Swine influenza: III. Filtration experiments and etiology. J. 
Exp. Med. 54:373-385. 
2. Murphy, B.R., and R.G. Webster. 1985. Orthomyxoviruses. In Fields Virology. 
B.N. Fields, and D.M. Knipe, editors. 1091-1152. 
3. Kawaoka, Y., N.J. Cox, O. Haller, S. Hongo, N. Kaverin, H.D. Klenk, R.A. 
Lamb, J. McCauley, P. Palese, E. Rimstad, and R.G. Webster. 2006. Index of 
Viruses - Orthomyxoviridae In ICTVdB. New York. 
4. Fouchier, R.A., V. Munster, A. Wallensten, T.M. Bestebroer, S. Herfst, D. Smith, 
G.F. Rimmelzwaan, B. Olsen, and A.D. Osterhaus. 2005. Characterization of a 
novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed 
gulls. J Virol 79:2814-2822. 
5. Webster, R.G., W.J. Bean, O.T. Gorman, T.M. Chambers, and Y. Kawaoka. 1992. 
Evolution and ecology of influenza A viruses. Microbiol Rev 56:152-179. 
6. Wilson, W.D. 1993. Equine influenza. Vet Clin North Am Equine Pract 9:257-
282. 
7. Mumford, J.A., and T.M. Chambers. 1998. Equine Influenza. In Textbook of 
Influenza. R.G.W. Karl G. Nicholson, Alan J. Hay, editor Blackwell Science, 
Oxford. 146-162. 
8. Ito, T., Y. Kawaoka, M. Ohira, H. Takakuwa, J. Yasuda, H. Kida, and K. Otsuki. 
1999. Replacement of internal protein genes, with the exception of the matrix, in 
equine 1 viruses by equine 2 influenza virus genes during evolution in nature. J 
Vet Med Sci 61:987-989. 
9. Webster, R.G. 1993. Are equine 1 influenza viruses still present in horses? Equine 
Vet J 25:537-538. 
10. Daly, J.M., A.C. Lai, M.M. Binns, T.M. Chambers, M. Barrandeguy, and J.A. 
Mumford. 1996. Antigenic and genetic evolution of equine H3N8 influenza A 
viruses. J Gen Virol 77 ( Pt 4):661-671. 
11. Lai, A.C., T.M. Chambers, R.E. Holland, Jr., P.S. Morley, D.M. Haines, H.G. 
Townsend, and M. Barrandeguy. 2001. Diverged evolution of recent equine-2 
influenza (H3N8) viruses in the Western Hemisphere. Arch Virol 146:1063-1074. 
12. Crawford, P.C., E.J. Dubovi, W.L. Castleman, I. Stephenson, E.P. Gibbs, L. 
Chen, C. Smith, R.C. Hill, P. Ferro, J. Pompey, R.A. Bright, M.J. Medina, C.M. 
Johnson, C.W. Olsen, N.J. Cox, A.I. Klimov, J.M. Katz, and R.O. Donis. 2005. 
Transmission of equine influenza virus to dogs. Science 310:482-485. 
13. Tu, J., H. Zhou, T. Jiang, C. Li, A. Zhang, X. Guo, W. Zou, H. Chen, and M. Jin. 
2009. Isolation and molecular characterization of equine H3N8 influenza viruses 
from pigs in China. Arch Virol 154:887-890. 
14. Choppin, P.W., J.S. Murphy, and I. Tamm. 1960. Studies of two kinds of virus 
particles which comprise influenza A2 virus strains. III. Morphological 
characteristics: independence to morphological and functional traits. J Exp Med 
112:945-952. 
15. Hoyle, L., R.W. Horne, and A.P. Waterson. 1961. The structure and composition 
of the myxoviruses. II. Components released from the influenza virus particle by 
ether. Virology 13:448-459. 
93 
 
16. Nicholson, K.G. 1998. Human Influenza. In Textbook of Influenza. R.G.W. Karl 
G. Nicholson, Alan J. Hay, editor Blackwell Science, Oxford. 219-264. 
17. Ulmanen, I., B.A. Broni, and R.M. Krug. 1981. Role of two of the influenza virus 
core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in 
initiating viral RNA transcription. Proc Natl Acad Sci U S A 78:7355-7359. 
18. Digard, P., V.C. Blok, and S.C. Inglis. 1989. Complex formation between 
influenza virus polymerase proteins expressed in Xenopus oocytes. Virology 
171:162-169. 
19. Biswas, S.K., P.L. Boutz, and D.P. Nayak. 1998. Influenza virus nucleoprotein 
interacts with influenza virus polymerase proteins. J Virol 72:5493-5501. 
20. Nakagawa, Y., K. Oda, and S. Nakada. 1996. The PB1 subunit alone can catalyze 
cRNA synthesis, and the PA subunit in addition to the PB1 subunit is required for 
viral RNA synthesis in replication of the influenza virus genome. J Virol 70:6390-
6394. 
21. Li, M.L., P. Rao, and R.M. Krug. 2001. The active sites of the influenza cap-
dependent endonuclease are on different polymerase subunits. EMBO J 20:2078-
2086. 
22. Chen, W., P.A. Calvo, D. Malide, J. Gibbs, U. Schubert, I. Bacik, S. Basta, R. 
O'Neill, J. Schickli, P. Palese, P. Henklein, J.R. Bennink, and J.W. Yewdell. 
2001. A novel influenza A virus mitochondrial protein that induces cell death. Nat 
Med 7:1306-1312. 
23. Sanz-Ezquerro, J.J., S. de la Luna, J. Ortin, and A. Nieto. 1995. Individual 
expression of influenza virus PA protein induces degradation of coexpressed 
proteins. J Virol 69:2420-2426. 
24. Fodor, E., M. Crow, L.J. Mingay, T. Deng, J. Sharps, P. Fechter, and G.G. 
Brownlee. 2002. A single amino acid mutation in the PA subunit of the influenza 
virus RNA polymerase inhibits endonucleolytic cleavage of capped RNAs. J 
Virol 76:8989-9001. 
25. Gamblin, S.J., L.F. Haire, R.J. Russell, D.J. Stevens, B. Xiao, Y. Ha, N. Vasisht, 
D.A. Steinhauer, R.S. Daniels, A. Elliot, D.C. Wiley, and J.J. Skehel. 2004. The 
structure and receptor binding properties of the 1918 influenza hemagglutinin. 
Science 303:1838-1842. 
26. Klenk, H.D., R. Rott, M. Orlich, and J. Blodorn. 1975. Activation of influenza A 
viruses by trypsin treatment. Virology 68:426-439. 
27. Rogers, G.N., and J.C. Paulson. 1983. Receptor determinants of human and 
animal influenza virus isolates: differences in receptor specificity of the H3 
hemagglutinin based on species of origin. Virology 127:361-373. 
28. Ito, T., J.N. Couceiro, S. Kelm, L.G. Baum, S. Krauss, M.R. Castrucci, I. 
Donatelli, H. Kida, J.C. Paulson, R.G. Webster, and Y. Kawaoka. 1998. 
Molecular basis for the generation in pigs of influenza A viruses with pandemic 
potential. J Virol 72:7367-7373. 
29. Skehel, J.J., P.M. Bayley, E.B. Brown, S.R. Martin, M.D. Waterfield, J.M. White, 
I.A. Wilson, and D.C. Wiley. 1982. Changes in the conformation of influenza 
virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc 
Natl Acad Sci U S A 79:968-972. 
94 
 
30. Baudin, F., C. Bach, S. Cusack, and R.W. Ruigrok. 1994. Structure of influenza 
virus RNP. I. Influenza virus nucleoprotein melts secondary structure in 
panhandle RNA and exposes the bases to the solvent. EMBO J 13:3158-3165. 
31. Wang, P., P. Palese, and R.E. O'Neill. 1997. The NPI-1/NPI-3 (karyopherin 
alpha) binding site on the influenza a virus nucleoprotein NP is a nonconventional 
nuclear localization signal. J Virol 71:1850-1856. 
32. Weber, F., G. Kochs, S. Gruber, and O. Haller. 1998. A classical bipartite nuclear 
localization signal on Thogoto and influenza A virus nucleoproteins. Virology 
250:9-18. 
33. Elton, D., E. Medcalf, K. Bishop, and P. Digard. 1999. Oligomerization of the 
influenza virus nucleoprotein: identification of positive and negative sequence 
elements. Virology 260:190-200. 
34. Ye, Z., T. Liu, D.P. Offringa, J. McInnis, and R.A. Levandowski. 1999. 
Association of influenza virus matrix protein with ribonucleoproteins. J Virol 
73:7467-7473. 
35. O'Neill, R.E., and P. Palese. 1995. NPI-1, the human homolog of SRP-1, interacts 
with influenza virus nucleoprotein. Virology 206:116-125. 
36. Digard, P., D. Elton, K. Bishop, E. Medcalf, A. Weeds, and B. Pope. 1999. 
Modulation of nuclear localization of the influenza virus nucleoprotein through 
interaction with actin filaments. J Virol 73:2222-2231. 
37. Elton, D., M. Simpson-Holley, K. Archer, L. Medcalf, R. Hallam, J. McCauley, 
and P. Digard. 2001. Interaction of the influenza virus nucleoprotein with the 
cellular CRM1-mediated nuclear export pathway. J Virol 75:408-419. 
38. Momose, F., C.F. Basler, R.E. O'Neill, A. Iwamatsu, P. Palese, and K. Nagata. 
2001. Cellular splicing factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the 
influenza virus nucleoprotein and enhances viral RNA synthesis. J Virol 75:1899-
1908. 
39. Turan, K., M. Mibayashi, K. Sugiyama, S. Saito, A. Numajiri, and K. Nagata. 
2004. Nuclear MxA proteins form a complex with influenza virus NP and inhibit 
the transcription of the engineered influenza virus genome. Nucleic Acids Res 
32:643-652. 
40. Gottschalk, A. 1957. Neuraminidase: the specific enzyme of influenza virus and 
Vibrio cholerae. Biochim Biophys Acta 23:645-646. 
41. Colman, P.M., J.N. Varghese, and W.G. Laver. 1983. Structure of the catalytic 
and antigenic sites in influenza virus neuraminidase. Nature 303:41-44. 
42. Palese, P., K. Tobita, M. Ueda, and R.W. Compans. 1974. Characterization of 
temperature sensitive influenza virus mutants defective in neuraminidase. 
Virology 61:397-410. 
43. Liu, C., M.C. Eichelberger, R.W. Compans, and G.M. Air. 1995. Influenza type A 
virus neuraminidase does not play a role in viral entry, replication, assembly, or 
budding. J Virol 69:1099-1106. 
44. Enami, M., and K. Enami. 1996. Influenza virus hemagglutinin and 
neuraminidase glycoproteins stimulate the membrane association of the matrix 
protein. J Virol 70:6653-6657. 
45. Ye, Z.P., R. Pal, J.W. Fox, and R.R. Wagner. 1987. Functional and antigenic 
domains of the matrix (M1) protein of influenza A virus. J Virol 61:239-246. 
95 
 
46. Bui, M., E.G. Wills, A. Helenius, and G.R. Whittaker. 2000. Role of the influenza 
virus M1 protein in nuclear export of viral ribonucleoproteins. J Virol 74:1781-
1786. 
47. Gomez-Puertas, P., C. Albo, E. Perez-Pastrana, A. Vivo, and A. Portela. 2000. 
Influenza virus matrix protein is the major driving force in virus budding. J Virol 
74:11538-11547. 
48. Lamb, R.A., S.L. Zebedee, and C.D. Richardson. 1985. Influenza virus M2 
protein is an integral membrane protein expressed on the infected-cell surface. 
Cell 40:627-633. 
49. Sugrue, R.J., and A.J. Hay. 1991. Structural characteristics of the M2 protein of 
influenza A viruses: evidence that it forms a tetrameric channel. Virology 
180:617-624. 
50. Nemeroff, M.E., X.Y. Qian, and R.M. Krug. 1995. The influenza virus NS1 
protein forms multimers in vitro and in vivo. Virology 212:422-428. 
51. Marion, R.M., T. Zurcher, S. de la Luna, and J. Ortin. 1997. Influenza virus NS1 
protein interacts with viral transcription-replication complexes in vivo. J Gen 
Virol 78 ( Pt 10):2447-2451. 
52. Wolstenholme, A.J., T. Barrett, S.T. Nichol, and B.W. Mahy. 1980. Influenza 
virus-specific RNA and protein syntheses in cells infected with temperature-
sensitive mutants defective in the genome segment encoding nonstructural 
proteins. J Virol 35:1-7. 
53. de la Luna, S., P. Fortes, A. Beloso, and J. Ortin. 1995. Influenza virus NS1 
protein enhances the rate of translation initiation of viral mRNAs. J Virol 
69:2427-2433. 
54. Qian, X.Y., F. Alonso-Caplen, and R.M. Krug. 1994. Two functional domains of 
the influenza virus NS1 protein are required for regulation of nuclear export of 
mRNA. J Virol 68:2433-2441. 
55. Qian, X.Y., C.Y. Chien, Y. Lu, G.T. Montelione, and R.M. Krug. 1995. An 
amino-terminal polypeptide fragment of the influenza virus NS1 protein possesses 
specific RNA-binding activity and largely helical backbone structure. RNA 1:948-
956. 
56. Wang, X., M. Li, H. Zheng, T. Muster, P. Palese, A.A. Beg, and A. Garcia-Sastre. 
2000. Influenza A virus NS1 protein prevents activation of NF-kappaB and 
induction of alpha/beta interferon. J Virol 74:11566-11573. 
57. Talon, J., C.M. Horvath, R. Polley, C.F. Basler, T. Muster, P. Palese, and A. 
Garcia-Sastre. 2000. Activation of interferon regulatory factor 3 is inhibited by 
the influenza A virus NS1 protein. J Virol 74:7989-7996. 
58. Ludwig, S., X. Wang, C. Ehrhardt, H. Zheng, N. Donelan, O. Planz, S. Pleschka, 
A. Garcia-Sastre, G. Heins, and T. Wolff. 2002. The influenza A virus NS1 
protein inhibits activation of Jun N-terminal kinase and AP-1 transcription 
factors. J Virol 76:11166-11171. 
59. Mibayashi, M., L. Martinez-Sobrido, Y.M. Loo, W.B. Cardenas, M. Gale, Jr., and 
A. Garcia-Sastre. 2007. Inhibition of retinoic acid-inducible gene I-mediated 
induction of beta interferon by the NS1 protein of influenza A virus. J Virol 
81:514-524. 
96 
 
60. Min, J.Y., and R.M. Krug. 2006. The primary function of RNA binding by the 
influenza A virus NS1 protein in infected cells: Inhibiting the 2'-5' oligo (A) 
synthetase/RNase L pathway. Proc Natl Acad Sci U S A 103:7100-7105. 
61. Nemeroff, M.E., S.M. Barabino, Y. Li, W. Keller, and R.M. Krug. 1998. 
Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF 
and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell 1:991-1000. 
62. Chen, Z., Y. Li, and R.M. Krug. 1999. Influenza A virus NS1 protein targets 
poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J 
18:2273-2283. 
63. Min, J.Y., S. Li, G.C. Sen, and R.M. Krug. 2007. A site on the influenza A virus 
NS1 protein mediates both inhibition of PKR activation and temporal regulation 
of viral RNA synthesis. Virology 363:236-243. 
64. Fernandez-Sesma, A., S. Marukian, B.J. Ebersole, D. Kaminski, M.S. Park, T. 
Yuen, S.C. Sealfon, A. Garcia-Sastre, and T.M. Moran. 2006. Influenza virus 
evades innate and adaptive immunity via the NS1 protein. J Virol 80:6295-6304. 
65. Richardson, J.C., and R.K. Akkina. 1991. NS2 protein of influenza virus is found 
in purified virus and phosphorylated in infected cells. Arch Virol 116:69-80. 
66. O'Neill, R.E., J. Talon, and P. Palese. 1998. The influenza virus NEP (NS2 
protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J 17:288-
296. 
67. Neumann, G., M.T. Hughes, and Y. Kawaoka. 2000. Influenza A virus NS2 
protein mediates vRNP nuclear export through NES-independent interaction with 
hCRM1. EMBO J 19:6751-6758. 
68. Robb, N.C., M. Smith, F.T. Vreede, and E. Fodor. 2009. The NS2/NEP Protein 
Regulates Transcription and Replication of the Influenza Virus RNA Genome. J 
Gen Virol  
69. Matlin, K.S., H. Reggio, A. Helenius, and K. Simons. 1981. Infectious entry 
pathway of influenza virus in a canine kidney cell line. J Cell Biol 91:601-613. 
70. Rust, M.J., M. Lakadamyali, F. Zhang, and X. Zhuang. 2004. Assembly of 
endocytic machinery around individual influenza viruses during viral entry. Nat 
Struct Mol Biol 11:567-573. 
71. Hatada, E., M. Hasegawa, J. Mukaigawa, K. Shimizu, and R. Fukuda. 1989. 
Control of influenza virus gene expression: quantitative analysis of each viral 
RNA species in infected cells. J Biochem 105:537-546. 
72. Webster, R.G., M. Yakhno, V.S. Hinshaw, W.J. Bean, and K.G. Murti. 1978. 
Intestinal influenza: replication and characterization of influenza viruses in ducks. 
Virology 84:268-278. 
73. Alexander, D.J. 2000. A review of avian influenza in different bird species. Vet 
Microbiol 74:3-13. 
74. Lu, Y., X.Y. Qian, and R.M. Krug. 1994. The influenza virus NS1 protein: a 
novel inhibitor of pre-mRNA splicing. Genes Dev 8:1817-1828. 
75. Brydon, E.W., H. Smith, and C. Sweet. 2003. Influenza A virus-induced apoptosis 
in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine 
release. J Gen Virol 84:2389-2400. 
76. Morris, S.J., G.E. Price, J.M. Barnett, S.A. Hiscox, H. Smith, and C. Sweet. 1999. 
Role of neuraminidase in influenza virus-induced apoptosis. J Gen Virol 80 ( Pt 
1):137-146. 
97 
 
77. Schultz-Cherry, S., N. Dybdahl-Sissoko, G. Neumann, Y. Kawaoka, and V.S. 
Hinshaw. 2001. Influenza virus ns1 protein induces apoptosis in cultured cells. J 
Virol 75:7875-7881. 
78. Kuiken, T., G.F. Rimmelzwaan, G. Van Amerongen, and A.D. Osterhaus. 2003. 
Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques 
(Macaca fascicularis). Vet Pathol 40:304-310. 
79. Steinhauer, D.A. 1999. Role of hemagglutinin cleavage for the pathogenicity of 
influenza virus. Virology 258:1-20. 
80. Senne, D.A., B. Panigrahy, Y. Kawaoka, J.E. Pearson, J. Suss, M. Lipkind, H. 
Kida, and R.G. Webster. 1996. Survey of the hemagglutinin (HA) cleavage site 
sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA 
cleavage site as a marker of pathogenicity potential. Avian Dis 40:425-437. 
81. Kawaoka, Y. 1991. Equine H7N7 influenza A viruses are highly pathogenic in 
mice without adaptation: potential use as an animal model. J Virol 65:3891-3894. 
82. Bottcher, E., T. Matrosovich, M. Beyerle, H.D. Klenk, W. Garten, and M. 
Matrosovich. 2006. Proteolytic activation of influenza viruses by serine proteases 
TMPRSS2 and HAT from human airway epithelium. J Virol 80:9896-9898. 
83. Hatta, M., P. Gao, P. Halfmann, and Y. Kawaoka. 2001. Molecular basis for high 
virulence of Hong Kong H5N1 influenza A viruses. Science 293:1840-1842. 
84. Goto, H., and Y. Kawaoka. 1998. A novel mechanism for the acquisition of 
virulence by a human influenza A virus. Proc Natl Acad Sci U S A 95:10224-
10228. 
85. Tumpey, T.M., C.F. Basler, P.V. Aguilar, H. Zeng, A. Solorzano, D.E. Swayne, 
N.J. Cox, J.M. Katz, J.K. Taubenberger, P. Palese, and A. Garcia-Sastre. 2005. 
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. 
Science 310:77-80. 
86. McAuley, J.L., F. Hornung, K.L. Boyd, A.M. Smith, R. McKeon, J. Bennink, 
J.W. Yewdell, and J.A. McCullers. 2007. Expression of the 1918 influenza A 
virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial 
pneumonia. Cell Host Microbe 2:240-249. 
87. Obenauer, J.C., J. Denson, P.K. Mehta, X. Su, S. Mukatira, D.B. Finkelstein, X. 
Xu, J. Wang, J. Ma, Y. Fan, K.M. Rakestraw, R.G. Webster, E. Hoffmann, S. 
Krauss, J. Zheng, Z. Zhang, and C.W. Naeve. 2006. Large-scale sequence 
analysis of avian influenza isolates. Science 311:1576-1580. 
88. Salvatore, M., A. Garcia-Sastre, P. Ruchala, R.I. Lehrer, T. Chang, and M.E. 
Klotman. 2007. alpha-Defensin inhibits influenza virus replication by cell-
mediated mechanism(s). J Infect Dis 196:835-843. 
89. Kopf, M., B. Abel, A. Gallimore, M. Carroll, and M.F. Bachmann. 2002. 
Complement component C3 promotes T-cell priming and lung migration to 
control acute influenza virus infection. Nat Med 8:373-378. 
90. Beebe, D.P., R.D. Schreiber, and N.R. Cooper. 1983. Neutralization of influenza 
virus by normal human sera: mechanisms involving antibody and complement. J 
Immunol 130:1317-1322. 
91. Anders, E.M., C.A. Hartley, P.C. Reading, and R.A. Ezekowitz. 1994. 
Complement-dependent neutralization of influenza virus by a serum mannose-
binding lectin. J Gen Virol 75 ( Pt 3):615-622. 
98 
 
92. Jayasekera, J.P., E.A. Moseman, and M.C. Carroll. 2007. Natural antibody and 
complement mediate neutralization of influenza virus in the absence of prior 
immunity. J Virol 81:3487-3494. 
93. Ezekowitz, R.A., L.E. Day, and G.A. Herman. 1988. A human mannose-binding 
protein is an acute-phase reactant that shares sequence homology with other 
vertebrate lectins. J Exp Med 167:1034-1046. 
94. Voorhout, W.F., T. Veenendaal, Y. Kuroki, Y. Ogasawara, L.M. van Golde, and 
H.J. Geuze. 1992. Immunocytochemical localization of surfactant protein D (SP-
D) in type II cells, Clara cells, and alveolar macrophages of rat lung. J Histochem 
Cytochem 40:1589-1597. 
95. Iobst, S.T., M.R. Wormald, W.I. Weis, R.A. Dwek, and K. Drickamer. 1994. 
Binding of sugar ligands to Ca(2+)-dependent animal lectins. I. Analysis of 
mannose binding by site-directed mutagenesis and NMR. J Biol Chem 
269:15505-15511. 
96. van de Wetering, J.K., L.M. van Golde, and J.J. Batenburg. 2004. Collectins: 
players of the innate immune system. Eur J Biochem 271:1229-1249. 
97. Kase, T., Y. Suzuki, T. Kawai, T. Sakamoto, K. Ohtani, S. Eda, A. Maeda, Y. 
Okuno, T. Kurimura, and N. Wakamiya. 1999. Human mannan-binding lectin 
inhibits the infection of influenza A virus without complement. Immunology 
97:385-392. 
98. Hartshorn, K.L., M.R. White, V. Shepherd, K. Reid, J.C. Jensenius, and E.C. 
Crouch. 1997. Mechanisms of anti-influenza activity of surfactant proteins A and 
D: comparison with serum collectins. Am J Physiol 273:L1156-1166. 
99. Hartshorn, K.L., K.B. Reid, M.R. White, J.C. Jensenius, S.M. Morris, A.I. 
Tauber, and E. Crouch. 1996. Neutrophil deactivation by influenza A viruses: 
mechanisms of protection after viral opsonization with collectins and 
hemagglutination-inhibiting antibodies. Blood 87:3450-3461. 
100. Lemaitre, B., E. Nicolas, L. Michaut, J.M. Reichhart, and J.A. Hoffmann. 1996. 
The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent 
antifungal response in Drosophila adults. Cell 86:973-983. 
101. Medzhitov, R., P. Preston-Hurlburt, and C.A. Janeway, Jr. 1997. A human 
homologue of the Drosophila Toll protein signals activation of adaptive 
immunity. Nature 388:394-397. 
102. Takeda, K., and S. Akira. 2007. Toll-like receptors. Curr Protoc Immunol Chapter 
14:Unit 14 12. 
103. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat Rev Immunol 
4:499-511. 
104. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int 
Immunol 17:1-14. 
105. Lund, J.M., L. Alexopoulou, A. Sato, M. Karow, N.C. Adams, N.W. Gale, A. 
Iwasaki, and R.A. Flavell. 2004. Recognition of single-stranded RNA viruses by 
Toll-like receptor 7. Proc Natl Acad Sci U S A 101:5598-5603. 
106. Guillot, L., R. Le Goffic, S. Bloch, N. Escriou, S. Akira, M. Chignard, and M. Si-
Tahar. 2005. Involvement of toll-like receptor 3 in the immune response of lung 
epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 
280:5571-5580. 
99 
 
107. Koyama, S., K.J. Ishii, H. Kumar, T. Tanimoto, C. Coban, S. Uematsu, T. Kawai, 
and S. Akira. 2007. Differential role of TLR- and RLR-signaling in the immune 
responses to influenza A virus infection and vaccination. J Immunol 179:4711-
4720. 
108. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate 
immunity. Cell 124:783-801. 
109. Meylan, E., J. Tschopp, and M. Karin. 2006. Intracellular pattern recognition 
receptors in the host response. Nature 442:39-44. 
110. Loo, Y.M., J. Fornek, N. Crochet, G. Bajwa, O. Perwitasari, L. Martinez-Sobrido, 
S. Akira, M.A. Gill, A. Garcia-Sastre, M.G. Katze, and M. Gale, Jr. 2008. Distinct 
RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 82:335-
345. 
111. Allen, I.C., M.A. Scull, C.B. Moore, E.K. Holl, E. McElvania-TeKippe, D.J. 
Taxman, E.H. Guthrie, R.J. Pickles, and J.P. Ting. 2009. The NLRP3 
inflammasome mediates in vivo innate immunity to influenza A virus through 
recognition of viral RNA. Immunity 30:556-565. 
112. Ichinohe, T., H.K. Lee, Y. Ogura, R. Flavell, and A. Iwasaki. 2009. 
Inflammasome recognition of influenza virus is essential for adaptive immune 
responses. J Exp Med 206:79-87. 
113. Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat 
Rev Immunol 5:953-964. 
114. Rodgers, B., and C.A. Mims. 1981. Interaction of influenza virus with mouse 
macrophages. Infect Immun 31:751-757. 
115. Hofmann, P., H. Sprenger, A. Kaufmann, A. Bender, C. Hasse, M. Nain, and D. 
Gemsa. 1997. Susceptibility of mononuclear phagocytes to influenza A virus 
infection and possible role in the antiviral response. J Leukoc Biol 61:408-414. 
116. Kaufmann, A., R. Salentin, R.G. Meyer, D. Bussfeld, C. Pauligk, H. Fesq, P. 
Hofmann, M. Nain, D. Gemsa, and H. Sprenger. 2001. Defense against influenza 
A virus infection: essential role of the chemokine system. Immunobiology 
204:603-613. 
117. Steinman, R.M., and Z.A. Cohn. 1973. Identification of a novel cell type in 
peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue 
distribution. J Exp Med 137:1142-1162. 
118. Steinman, R.M. 1999. Dendritic Cells. In Fundamental Immunology. W.E. Paul, 
editor Philadelphia. 547-573. 
119. D'Amico, A., and L. Wu. 2003. The early progenitors of mouse dendritic cells and 
plasmacytoid predendritic cells are within the bone marrow hemopoietic 
precursors expressing Flt3. J Exp Med 198:293-303. 
120. Karsunky, H., M. Merad, A. Cozzio, I.L. Weissman, and M.G. Manz. 2003. Flt3 
ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-
committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 198:305-313. 
121. Varol, C., L. Landsman, D.K. Fogg, L. Greenshtein, B. Gildor, R. Margalit, V. 
Kalchenko, F. Geissmann, and S. Jung. 2007. Monocytes give rise to mucosal, but 
not splenic, conventional dendritic cells. J Exp Med 204:171-180. 
122. Shortman, K., and Y.J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat 
Rev Immunol 2:151-161. 
100 
 
123. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use 
macropinocytosis and the mannose receptor to concentrate macromolecules in the 
major histocompatibility complex class II compartment: downregulation by 
cytokines and bacterial products. J Exp Med 182:389-400. 
124. Lopez, C.B., A. Garcia-Sastre, B.R. Williams, and T.M. Moran. 2003. Type I 
interferon induction pathway, but not released interferon, participates in the 
maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis 
187:1126-1136. 
125. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of 
immunity. Nature 392:245-252. 
126. Reis e Sousa, C. 2006. Dendritic cells in a mature age. Nat Rev Immunol 6:476-
483. 
127. Kapsenberg, M.L. 2003. Dendritic-cell control of pathogen-driven T-cell 
polarization. Nat Rev Immunol 3:984-993. 
128. Siedek, E., S. Little, S. Mayall, N. Edington, and A. Hamblin. 1997. Isolation and 
characterisation of equine dendritic cells. Vet Immunol Immunopathol 60:15-31. 
129. Hammond, S.A., D. Horohov, and R.C. Montelaro. 1999. Functional 
characterization of equine dendritic cells propagated ex vivo using recombinant 
human GM-CSF and recombinant equine IL-4. Vet Immunol Immunopathol 
71:197-214. 
130. Cavatorta, D.J., H.N. Erb, and M.J. Flaminio. 2009. Ex vivo generation of mature 
equine monocyte-derived dendritic cells. Vet Immunol Immunopathol 131:259-
267. 
131. Bender, A., M. Albert, A. Reddy, M. Feldman, B. Sauter, G. Kaplan, W. Hellman, 
and N. Bhardwaj. 1998. The distinctive features of influenza virus infection of 
dendritic cells. Immunobiology 198:552-567. 
132. Lopez, C.B., A. Fernandez-Sesma, S.M. Czelusniak, J.L. Schulman, and T.M. 
Moran. 2000. A mouse model for immunization with ex vivo virus-infected 
dendritic cells. Cell Immunol 206:107-115. 
133. Bhardwaj, N., A. Bender, N. Gonzalez, L.K. Bui, M.C. Garrett, and R.M. 
Steinman. 1994. Influenza virus-infected dendritic cells stimulate strong 
proliferative and cytolytic responses from human CD8+ T cells. J Clin Invest 
94:797-807. 
134. Sareneva, T., S. Matikainen, M. Kurimoto, and I. Julkunen. 1998. Influenza A 
virus-induced IFN-alpha/beta and IL-18 synergistically enhance IFN-gamma gene 
expression in human T cells. J Immunol 160:6032-6038. 
135. Stetson, D.B., M. Mohrs, R.L. Reinhardt, J.L. Baron, Z.E. Wang, L. Gapin, M. 
Kronenberg, and R.M. Locksley. 2003. Constitutive cytokine mRNAs mark 
natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 
198:1069-1076. 
136. Fehniger, T.A., S.F. Cai, X. Cao, A.J. Bredemeyer, R.M. Presti, A.R. French, and 
T.J. Ley. 2007. Acquisition of murine NK cell cytotoxicity requires the translation 
of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26:798-811. 
137. Chiorean, E.G., and J.S. Miller. 2001. The biology of natural killer cells and 
implications for therapy of human disease. J Hematother Stem Cell Res 10:451-
463. 
101 
 
138. Cheent, K., and S.I. Khakoo. 2009. Natural killer cells: integrating diversity with 
function. Immunology 126:449-457. 
139. Stein-Streilein, J., and J. Guffee. 1986. In vivo treatment of mice and hamsters 
with antibodies to asialo GM1 increases morbidity and mortality to pulmonary 
influenza infection. J Immunol 136:1435-1441. 
140. Gazit, R., R. Gruda, M. Elboim, T.I. Arnon, G. Katz, H. Achdout, J. Hanna, U. 
Qimron, G. Landau, E. Greenbaum, Z. Zakay-Rones, A. Porgador, and O. 
Mandelboim. 2006. Lethal influenza infection in the absence of the natural killer 
cell receptor gene Ncr1. Nat Immunol 7:517-523. 
141. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T.I. Arnon, Y. Bushkin, D.M. 
Davis, J.L. Strominger, J.W. Yewdell, and A. Porgador. 2001. Recognition of 
haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK 
cells. Nature 409:1055-1060. 
142. Arnon, T.I., M. Lev, G. Katz, Y. Chernobrov, A. Porgador, and O. Mandelboim. 
2001. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J 
Immunol 31:2680-2689. 
143. Guillonneau, C., J.D. Mintern, F.X. Hubert, A.C. Hurt, G.S. Besra, S. Porcelli, 
I.G. Barr, P.C. Doherty, D.I. Godfrey, and S.J. Turner. 2009. Combined NKT cell 
activation and influenza virus vaccination boosts memory CTL generation and 
protective immunity. Proc Natl Acad Sci U S A 106:3330-3335. 
144. Liu, Y.J. 2005. IPC: professional type 1 interferon-producing cells and 
plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275-306. 
145. Krug, R.M., M. Shaw, B. Broni, G. Shapiro, and O. Haller. 1985. Inhibition of 
influenza viral mRNA synthesis in cells expressing the interferon-induced Mx 
gene product. J Virol 56:201-206. 
146. Zuniga-Pflucker, J.C., and M.J. Lenardo. 1996. Regulation of thymocyte 
development from immature progenitors. Curr Opin Immunol 8:215-224. 
147. Berke, G. 1995. The CTL's kiss of death. Cell 81:9-12. 
148. Lawrence, C.W., and T.J. Braciale. 2004. Activation, differentiation, and 
migration of naive virus-specific CD8+ T cells during pulmonary influenza virus 
infection. J Immunol 173:1209-1218. 
149. Lawrence, C.W., R.M. Ream, and T.J. Braciale. 2005. Frequency, specificity, and 
sites of expansion of CD8+ T cells during primary pulmonary influenza virus 
infection. J Immunol 174:5332-5340. 
150. Mintern, J.D., C. Guillonneau, F.R. Carbone, P.C. Doherty, and S.J. Turner. 2007. 
Cutting edge: Tissue-resident memory CTL down-regulate cytolytic molecule 
expression following virus clearance. J Immunol 179:7220-7224. 
151. Barber, D.L., E.J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo 
killing by memory CD8 T cells. J Immunol 171:27-31. 
152. Abbas, A.K., K.M. Murphy, and A. Sher. 1996. Functional diversity of helper T 
lymphocytes. Nature 383:787-793. 
153. Brown, D.M., A.M. Dilzer, D.L. Meents, and S.L. Swain. 2006. CD4 T cell-
mediated protection from lethal influenza: perforin and antibody-mediated 
mechanisms give a one-two punch. J Immunol 177:2888-2898. 
154. Riberdy, J.M., J.P. Christensen, K. Branum, and P.C. Doherty. 2000. Diminished 
primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-
depleted Ig(-/-) mice. J Virol 74:9762-9765. 
102 
 
155. Homann, D., L. Teyton, and M.B. Oldstone. 2001. Differential regulation of 
antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell 
memory. Nat Med 7:913-919. 
156. LeBien, T.W., and T.F. Tedder. 2008. B lymphocytes: how they develop and 
function. Blood 112:1570-1580. 
157. Lanzavecchia, A. 1985. Antigen-specific interaction between T and B cells. 
Nature 314:537-539. 
158. Baumgarth, N., O.C. Herman, G.C. Jager, L. Brown, and L.A. Herzenberg. 1999. 
Innate and acquired humoral immunities to influenza virus are mediated by 
distinct arms of the immune system. Proc Natl Acad Sci U S A 96:2250-2255. 
159. Graham, M.B., and T.J. Braciale. 1997. Resistance to and recovery from lethal 
influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186:2063-
2068. 
160. Mozdzanowska, K., K. Maiese, and W. Gerhard. 2000. Th cell-deficient mice 
control influenza virus infection more effectively than Th- and B cell-deficient 
mice: evidence for a Th-independent contribution by B cells to virus clearance. J 
Immunol 164:2635-2643. 
161. Palladino, G., K. Mozdzanowska, G. Washko, and W. Gerhard. 1995. Virus-
neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA 
isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69:2075-2081. 
162. Mozdzanowska, K., M. Furchner, G. Washko, J. Mozdzanowski, and W. Gerhard. 
1997. A pulmonary influenza virus infection in SCID mice can be cured by 
treatment with hemagglutinin-specific antibodies that display very low virus-
neutralizing activity in vitro. J Virol 71:4347-4355. 
163. Joo, H.M., Y. He, and M.Y. Sangster. 2008. Broad dispersion and lung 
localization of virus-specific memory B cells induced by influenza pneumonia. 
Proc Natl Acad Sci U S A 105:3485-3490. 
164. Luft, T., K.C. Pang, E. Thomas, P. Hertzog, D.N. Hart, J. Trapani, and J. Cebon. 
1998. Type I IFNs enhance the terminal differentiation of dendritic cells. J 
Immunol 161:1947-1953. 
165. Lei, L., and J.M. Hostetter. 2007. Limited phenotypic and functional maturation 
of bovine monocyte-derived dendritic cells following Mycobacterium avium 
subspecies paratuberculosis infection in vitro. Vet Immunol Immunopathol 
120:177-186. 
166. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen 
by cultured human dendritic cells is maintained by granulocyte/macrophage 
colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis 
factor alpha. J Exp Med 179:1109-1118. 
167. Bender, A., M. Sapp, G. Schuler, R.M. Steinman, and N. Bhardwaj. 1996. 
Improved methods for the generation of dendritic cells from nonproliferating 
progenitors in human blood. J Immunol Methods 196:121-135. 
168. Allavena, P., L. Piemonti, D. Longoni, S. Bernasconi, A. Stoppacciaro, L. Ruco, 
and A. Mantovani. 1998. IL-10 prevents the differentiation of monocytes to 
dendritic cells but promotes their maturation to macrophages. Eur J Immunol 
28:359-369. 
103 
 
169. Chomarat, P., J. Banchereau, J. Davoust, and A.K. Palucka. 2000. IL-6 switches 
the differentiation of monocytes from dendritic cells to macrophages. Nat 
Immunol 1:510-514. 
170. Geissmann, F., S. Jung, and D.R. Littman. 2003. Blood monocytes consist of two 
principal subsets with distinct migratory properties. Immunity 19:71-82. 
171. Naik, S.H., D. Metcalf, A. van Nieuwenhuijze, I. Wicks, L. Wu, M. O'Keeffe, and 
K. Shortman. 2006. Intrasplenic steady-state dendritic cell precursors that are 
distinct from monocytes. Nat Immunol 7:663-671. 
172. Sprenger, H., R.G. Meyer, A. Kaufmann, D. Bussfeld, E. Rischkowsky, and D. 
Gemsa. 1996. Selective induction of monocyte and not neutrophil-attracting 
chemokines after influenza A virus infection. J Exp Med 184:1191-1196. 
173. Gill, M.A., K. Long, T. Kwon, L. Muniz, A. Mejias, J. Connolly, L. Roy, J. 
Banchereau, and O. Ramilo. 2008. Differential recruitment of dendritic cells and 
monocytes to respiratory mucosal sites in children with influenza virus or 
respiratory syncytial virus infection. J Infect Dis 198:1667-1676. 
174. Quinlivan, M., D. Zamarin, A. Garcia-Sastre, A. Cullinane, T. Chambers, and P. 
Palese. 2005. Attenuation of equine influenza viruses through truncations of the 
NS1 protein. J Virol 79:8431-8439. 
175. Reed, L.J., and H. Muench. 1938. A simple method of estimating fifty per cent 
endpoints. Am. J. Hygiene. 27:493-497. 
176. Merant, C., C.C. Breathnach, K. Kohler, C. Rashid, P. Van Meter, and D.W. 
Horohov. 2009. Young foal and adult horse monocyte-derived dendritic cells 
differ by their degree of phenotypic maturity. Vet Immunol Immunopathol  
177. Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
25:402-408. 
178. Horohov, D.W., C.C. Breathnach, T.L. Sturgill, C. Rashid, J.L. Stiltner, D. 
Strong, N. Nieman, and R.E. Holland. 2008. In vitro and in vivo modulation of 
the equine immune response by parapoxvirus ovis. Equine Vet J 40:468-472. 
179. Yam, L.T., C.Y. Li, and W.H. Crosby. 1971. Cytochemical identification of 
monocytes and granulocytes. Am J Clin Pathol 55:283-290. 
180. Horwitz, D.A., A.C. Allison, P. Ward, and N. Kight. 1977. Identification of 
human mononuclear leucocyte populations by esterase staining. Clin Exp 
Immunol 30:289-298. 
181. Rademakers, L.H., W.T. Van Blokland, J.F. De Frankrijker, R.A. De Weger, and 
P.I. Compier-Spies. 1989. Ultrastructural cytochemistry of non-specific esterase 
in murine peritoneal macrophages. Histochem J 21:301-308. 
182. Reibman, J., A.T. Talbot, Y. Hsu, G. Ou, J. Jover, D. Nilsen, and M.H. Pillinger. 
2000. Regulation of expression of granulocyte-macrophage colony-stimulating 
factor in human bronchial epithelial cells: roles of protein kinase C and mitogen-
activated protein kinases. J Immunol 165:1618-1625. 
183. Vliagoftis, H., A.D. Befus, M.D. Hollenberg, and R. Moqbel. 2001. Airway 
epithelial cells release eosinophil survival-promoting factors (GM-CSF) after 
stimulation of proteinase-activated receptor 2. J Allergy Clin Immunol 107:679-
685. 
184. Heidenreich, S., J.H. Gong, A. Schmidt, M. Nain, and D. Gemsa. 1989. 
Macrophage activation by granulocyte/macrophage colony-stimulating factor. 
104 
 
Priming for enhanced release of tumor necrosis factor-alpha and prostaglandin 
E2. J Immunol 143:1198-1205. 
185. Bender, A., U. Amann, R. Jager, M. Nain, and D. Gemsa. 1993. Effect of 
granulocyte/macrophage colony-stimulating factor on human monocytes infected 
with influenza A virus. Enhancement of virus replication, cytokine release, and 
cytotoxicity. J Immunol 151:5416-5424. 
186. Perno, C.F., R. Yarchoan, D.A. Cooney, N.R. Hartman, D.S. Webb, Z. Hao, H. 
Mitsuya, D.G. Johns, and S. Broder. 1989. Replication of human 
immunodeficiency virus in monocytes. Granulocyte/macrophage colony-
stimulating factor (GM-CSF) potentiates viral production yet enhances the 
antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other 
dideoxynucleoside congeners of thymidine. J Exp Med 169:933-951. 
187. Kalter, D.C., M. Nakamura, J.A. Turpin, L.M. Baca, D.L. Hoover, C. 
Dieffenbach, P. Ralph, H.E. Gendelman, and M.S. Meltzer. 1991. Enhanced HIV 
replication in macrophage colony-stimulating factor-treated monocytes. J 
Immunol 146:298-306. 
188. Boyer, J.D., B. Nath, K. Schumann, E. Curley, K. Manson, J. Kim, and D.B. 
Weiner. 2002. IL-4 increases Simian immunodeficiency virus replication despite 
enhanced SIV immune responses in infected rhesus macaques. Int J Parasitol 
32:543-550. 
189. Mock, D.J., F. Domurat, N.J. Roberts, Jr., E.E. Walsh, M.R. Licht, and P. Keng. 
1987. Macrophages are required for influenza virus infection of human 
lymphocytes. J Clin Invest 79:620-624. 
190. Wang, X., E.R. Hinson, and P. Cresswell. 2007. The interferon-inducible protein 
viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host 
Microbe 2:96-105. 
191. Van Campen, H. 1994. Influenza A virus replication is inhibited by tumor 
necrosis factor-alpha in vitro. Arch Virol 136:439-446. 
192. Wurster, A.L., V.L. Rodgers, M.F. White, T.L. Rothstein, and M.J. Grusby. 2002. 
Interleukin-4-mediated protection of primary B cells from apoptosis through 
Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 277:27169-27175. 
193. Carey, G.B., E. Semenova, X. Qi, and A.D. Keegan. 2007. IL-4 protects the B-
cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and 
apoptosis: contribution of the PI-3 kinase/AKT pathway. Cell Res 17:942-955. 
194. Zaba, L.C., J. Fuentes-Duculan, R.M. Steinman, J.G. Krueger, and M.A. Lowes. 
2007. Normal human dermis contains distinct populations of CD11c+BDCA-1+ 
dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 117:2517-2525. 
195. Assier, E., V. Marin-Esteban, A. Haziot, E. Maggi, D. Charron, and N. Mooney. 
2007. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and 
maturation. J Leukoc Biol 81:221-228. 
196. Hervas-Stubbs, S., A. Olivier, F. Boisgerault, N. Thieblemont, and C. Leclerc. 
2007. TLR3 ligand stimulates fully functional memory CD8+ T cells in the 
absence of CD4+ T-cell help. Blood 109:5318-5326. 
197. Zarnani, A.H., S.M. Moazzeni, F. Shokri, M. Salehnia, P. Dokouhaki, J. 
Shojaeian, and M. Jeddi-Tehrani. 2006. The efficient isolation of murine splenic 
dendritic cells and their cytochemical features. Histochem Cell Biol 126:275-282. 
105 
 
198. Mallon, D.F., A. Buck, J.C. Reece, S.M. Crowe, and P.U. Cameron. 1999. 
Monocyte-derived dendritic cells as a model for the study of HIV-1 infection: 
productive infection and phenotypic changes during culture in human serum. 
Immunol Cell Biol 77:442-450. 
199. Strobl, H., E. Riedl, C. Scheinecker, C. Bello-Fernandez, W.F. Pickl, K. 
Rappersberger, O. Majdic, and W. Knapp. 1996. TGF-beta 1 promotes in vitro 
development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol 
157:1499-1507. 
200. Macatonia, S.E., N.A. Hosken, M. Litton, P. Vieira, C.S. Hsieh, J.A. Culpepper, 
M. Wysocka, G. Trinchieri, K.M. Murphy, and A. O'Garra. 1995. Dendritic cells 
produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. 
J Immunol 154:5071-5079. 
201. Graham, M.B., V.L. Braciale, and T.J. Braciale. 1994. Influenza virus-specific 
CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental 
virus infection. J Exp Med 180:1273-1282. 
202. Sun, K., L. Torres, and D.W. Metzger. 2008. A Detrimental Role for IL-10 
During Host Immune Responses to Influenza Virus Infection. FASEB J. 
22:857.855-. 
203. van der Sluijs, K.F., L.J. van Elden, M. Nijhuis, R. Schuurman, J.M. Pater, S. 
Florquin, M. Goldman, H.M. Jansen, R. Lutter, and T. van der Poll. 2004. IL-10 
is an important mediator of the enhanced susceptibility to pneumococcal 
pneumonia after influenza infection. J Immunol 172:7603-7609. 
204. McRae, B.L., T. Nagai, R.T. Semnani, J.M. van Seventer, and G.A. van Seventer. 
2000. Interferon-alpha and -beta inhibit the in vitro differentiation of 
immunocompetent human dendritic cells from CD14(+) precursors. Blood 
96:210-217. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
VITA 
SAIKAT BOLIAR 
 
 
Personal Information 
Date of Birth May 2nd, 1981 
 
Place of Birth West Bengal, India 
 
Nationality Indian 
 
 
 
Education 
 
B.V.Sc & A.H., 2004            West Bengal University of Animal and Fishery Sciences,  
                                            Kolkata, India 
 
 
Professional Training/Appointment 
2004-present   Research Assistant (Laboratory of Dr. T. M. Chambers) 
                             University of Kentucky, Department of Veterinary Science 
 
2004  Internship with veterinary hospitals, Kolkata, India 
 
 
  
Awards and Honors 
2007-present Geoffrey C. Hughes Fellowship 
 
2006 Induction to Gamma Sigma Delta Honor Society 
 
2005  Graduate School Academic Year Fellowship, University of 
                                            Kentucky 
 
1997-2004 National Scholarship, India  
 
       
 
Membership in Professional Society 
2007-present  American Society for Virology (ASV) 
 
 
 
107 
 
Peer-reviewed Publications 
1. Boliar, S., Stanislawek, W., Chambers, T. M. 2006. Inability of kaolin treatment to 
remove nonspecific inhibitors from equine serum for the hemagglutination 
inhibition test against equine H7N7 influenza virus. J. Vet. Diagn. Invest. 18:264-
7. (Won Best Brief Communication of the year award) 
2. Lu, Z., Chambers, T. M., Boliar, S., Timoney, P. J., Branscum, A. J., Reedy, S. E., 
Tudor, L., Dubovi, E. J., Vickers, M. L., Sells, S., Balasuriya, U. B. R. 2009. 
Development and evaluation of one-step TaqMan real-time reverse transcription 
PCR assays targeting NP, M and HA genes of equine influenza virus. J. Clin. 
Microbiol. (Submitted). 
3. Boliar, S., Horohov, D. W., Chambers, T. M. 2009. A new strategy of 
immunoevasion by influenza A virus: inhibition of monocyte differentiation into 
dendritic cell. (Manuscript in preparation). 
Abstracts/Presentations 
1. Boliar, S., Chambers, T. M. 2007. Characterization of temperature sensitive (ts) 
phenotype of Flu Avert™ I.N. equine influenza vaccine virus. 26th Annual Meeting 
of American Society for Virology (ASV). 
2. Boliar, S., Horohov, D. W., Chambers, T. M. 2008. A new strategy of immune 
evasion by influenza virus: inhibition of monocyte differentiation into dendritic 
cell. 27th Annual Meeting of American Society for Virology (ASV). 
  
 
